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Abstract
Photodynamic therapy (PDT) is a minimally invasive therapy form for the treatment of malig-
nant tumors, but also for other tissue changes, e.g. for acne. To perform PDT, a photosensitizer is 
activated by light, which induces cell death by the interaction with oxygen or by the direct for-
mation of radicals of those cells which took up the photosensitizer. The outcome of the treatment 
is influenced mainly by the concentration of oxygen and of the photosensitizer in the target tis-
sue, its triplet state quantum yield, the light dose applied and the time interval between applica-
tion of the photosensitizer and treatment, the so-called drug light interval (DLI). These parame-
ters have to be adjusted in such a way that ideally, all tumor cells are destroyed but the normal 
tissue stays intact. 
In the present thesis, protoporphyrin IX (PpIX) and temoporfin concentrations are evaluated 
in different tissue types after these photosensitizers have been applied for the treatment of malig-
nant glioma (PpIX) and cholangiocarcinoma (temoporfin). Analyzed is the dependency of the 
applied photosensitizer dose and the initial photosensitizer concentration in the target tissue on 
treatment outcome. In addition, pharmacokinetics that were obtained through concentration 
measurements are linked to the DLI. Aim of the investigation is to determine the relative and 
absolute photosensitizer concentrations in order to be able to optimize PDT in the future. 
The first part of this thesis concentrates on the investigation of PpIX accumulation in the dif-
ferent tumor parts (vital solid tumor tissue, infiltrating parts, necrotic tissue) and in glioma of 
different grades of malignancy (WHO grade III & IV). Tissue samples were evaluated that had 
been gathered during fluorescence guided resections (FGR), performed with 5-aminolevulinic 
acid (5-ALA), a precursor of PpIX, at the approved dose of 20 mg/kg body weight (Gliolan®,
medac GmbH, Wedel, Germany). Apart from the gain of knowledge on the accumulation of 
PpIX in the different tumor parts and grades of malignancy, the aim of this study was to deter-
mine whether the approved dose of 5-ALA is also effective in case of PDT.
Analyzed were tissue samples of 22 patients. On the basis of histological grading, tissue 
samples were divided into vital, infiltrating and necrotic grade IV, grade III as well as non-
neoplastic biopsies. The mean concentration of vital grade IV tumor tissue, 5.8 ± 4.8 μmol/l 
(n=8), differs significantly from the mean of grade III tumors, 0.2 ± 0.4 μmol/l (n=4). Infiltrating 
and necrotic tissue biopsies resulted in concentrations of 1.0 ± 1.0 μmol/l (n=4) and 
0.5 ± 0.5 μmol/l (n=4). Literature on the absolute PpIX concentration in human skin and human 
Barrett’s esophagus indicates that tissue damage is induced at a concentration of about 1 -
2 μmol/l and 2 - 9 μmol/l, respectively. Thus it can be assumed that a PDT for vital grade IV 
tumors is effective, while grade III tumors do not seem to be a responsive target. To draw a pre-
cise conclusion on infiltrating parts, an analysis on a cellular basis needs to be performed. The 
method used in this thesis however, is not suitable for a cellular PpIX concentration analysis. 
The second part of this thesis concentrates on the dependence of the outcome of interstitial 
PDT (iPDT) of malignant glioma on the initial photosensitizer concentration and the photo-
bleaching effect. Aim of the study was to further understand their correlation. 
In a pilot study, iPDT was performed on five patients with non-resectable glioblastoma mul-
tiforme (GBM) after administration of 20 or 30 mg/kg b. w. 5-ALA (Gliolan®, medac GmbH, 
Wedel, Germany). In each patient, the in vivo fluorescence in tissue was measured before and 
after radiation in order to determine the photobleaching effect by comparison. In addition, stereo-
tactic biopsies were taken before radiation, which were partly used for histological assessment 
and partly for determining the absolute photosensitizer concentration ex vivo. The PDT effec-
tiveness was determined on day 1 after iPDT via magnetic resonance imaging (MRI). The initial 
PpIX fluorescence intensity, the photobleaching effect, the histologic findings and the MRI im-
ages were correlated and all parameters compared with the follow-up. It could be demonstrated 
viii
that high initial PpIX concentrations (1.4 - 3.0 μmol/l) and strong photobleaching in three pa-
tients were accompanied by a good treatment result and long survival time (29, 30 and 36 
months). The biopsies of the remaining two patients showed low PpIX concentrations (0 -
0.6 μmol/l). Accordingly, before iPDT, no or only low fluorescence could be measured in vivo.
In agreement with the fluorescence data, good treatment results failed to appear, the patients died 
of the tumor after 3 and 9 months. These results indicate that, in order for a treatment to be effec-
tive, a minimum photosensitizer concentration needs to be present in tissue. In addition, an ap-
proach towards an applicable implicit dosimetry model for iPDT was taken by demonstrating an 
easy and safe implementation of in vivo fluorescence measurements. Through this implementa-
tion, an early prognosis of iPDT outcome seems possible. 
The third part of this thesis concentrates on the effectiveness of PDT for cholangiocarcino-
ma (CC) at low dose of meso-tetrahydroxyphenyl chlorine (mTHPC, Foscan®, Biolitec pharma 
Ltd., Dublin, Ireland). Literature shows that for treatment of CC, the combination of stenting and 
PDT performed with the photosensitizer porfimer sodium (Photofrin®) enhances the survival 
time by a mean of 265 days. However, side effects such as the photosensitivity of the patients, 
requiring shielding from direct sunlight for up to three months, and the risk of perforations of the 
organ walls through PDT demonstrate a restriction in PDT as palliative treatment for CC. The 
aim of this study was to investigate PDT of CC performed with Foscan® at a low dose, in order 
to introduce a treatment with the same outcome, while lowering the side effects. 
In this study, 14 PDTs were performed in 13, not specially selected, consecutive patients. 
Foscan®, which was approved in Europe in 2001 for the palliative treatment of head and neck 
cancer at a dose of 0.15 mg/kg b. w., a fluence of 20 J/cm2 and a DLI of 96 h, was administered 
to the patients at a mean dose of 0.44 ± 0.007 mg/kg b. w. (3 mg/patient), 50 J/cm and a DLI 
between 20 - 72 h. In 5 of the13 patients the relative fluorescence intensity was determined di-
rectly before PDT on the tumor and normal surrounding tissue. In another 4 of the 13 patients, 
normalized fluorescence kinetics were measured in the oral cavity, to gain data for optimizing 
the DLI. After analysis of the data, the DLI was adjusted from the initial 20 to 67 - 72 h. As indi-
cator for a successful treatment, the survival time of the PDT patients was evaluated with the 
Kaplan-Meier method. At the time of evaluation, the median survival time was 13 months. At 
the same time 8 of the 13 patients were still alive. Skin irritations or severe complications such 
as organ wall perforations could not be observed during the patients’ hospital stay and were not 
reported later on. The results of the 14 PDTs with Foscan® at a low dose which were performed 
in this study show the same treatment outcomes compared to Photofrin® PDT – while lowering 
the side effects and complications. In addition a treatment protocol was introduced, forming the 
base for studies with a greater patient collective. 
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Zusammenfassung
Die photodynamische Therapie (PDT) dient der minimalinvasiven Behandlung von malignen 
Tumoren, aber auch anderer Gewebeveränderungen wie z. B. der Akne. Bei der PDT wird ein 
Photosensibilisator mittels Licht aktiviert, der durch die Wechselwirkung mit Sauerstoff bzw. 
durch die direkte Erzeugung von Radikalen zum Tod der Zellen führt, die den Farbstoff aufge-
nommen haben. Beeinflusst wird das Therapieergebnis hauptsächlich durch den Sauerstoffgehalt 
und die Konzentration des Photosensibilisators im Zielgewebe, die Quantenausbeute seines 
Triplettzustands, die Dosierung des eingestrahlten Lichts und das Intervall zwischen Applikation 
des Photosensibilisators und der Behandlung, dem sogenannten Drug Light Interval (DLI). Diese 
Parameter müssen derart aufeinander abgestimmt sein, dass möglichst alle Tumorzellen aber 
kein Normalgewebe zerstört werden. 
In der vorliegenden Dissertation werden Konzentrationen von Protoporphyrin IX (PpIX) 
und Temoporfin in verschiedenen Gewebearten untersucht, nachdem diese Photosensibilisatoren
zur Behandlung von malignen Gliomen (PpIX) und Cholangiokarzinomen (Temoporfin) appli-
ziert wurden. Analysiert wird die Abhängigkeit des Behandlungsergebnisses von der applizierten 
Dosis und der initialen Photosensibilisatorkonzentration im Zielgewebe. Zusätzlich werden 
durch Konzentrationsmessungen erhaltene Pharmakokinetiken zum DLI in Bezug gesetzt. Ziel 
der Untersuchungen ist es, die PDT durch Bestimmung der relativen und absoluten Konzentrati-
onen des Photosensibilisators in Gewebe für zukünftige Behandlungen zu optimieren. 
Der erste Teil dieser Arbeit konzentriert sich auf Studien zur PpIX-Anreicherung in ver-
schiedenen Tumorbereichen (vitales solides Tumorgewebe, Infiltrationszone, nekrotisches Ge-
webe) und in Gliomen unterschiedlichen Malignitätsgrades (WHO Grad III & IV). Es wurden 
Gewebeproben untersucht, die während fluoreszenzgestützter Resektionen (FGR) entnommen 
wurden. Durchgeführt wurden die FGR mit 5-Aminolävulin Säure (5-ALA), einem Vorläufer 
von PpIX, in der zugelassenen Dosis von 20 mg/kg Körpergewicht (Gliolan®, medac GmbH, 
Wedel, Deutschland). Neben der Untersuchung der Anreicherung von PpIX in verschiedenen 
Tumorbereichen und in Tumoren verschiedenen Malignitätsgrades war das Ziel der Studie zu 
erforschen, ob die für die FGR zugelassene Dosis von 5-ALA ebenfalls für die PDT effektiv ist. 
Analysiert wurden Gewebestücke von 22 Patienten. Auf der Basis des histologischen Be-
fundes wurden die Gewebeproben in vitale, infiltrierende und nekrotische Grad IV-, Grad III-, 
sowie nicht-neoplastische Biopsien unterteilt. Die mittlere PpIX-Konzentration in vitalem Grad-
IV-Tumorgewebe unterscheidet sich mit 5,8 ± 4,8 μmol/l (n=8) signifikant von derjenigen der 
Grad-III-Tumore mit 0,2 ± 0,4 μmol/l (n=4). Für infiltrierend wachsende bzw. nekrotische Ge-
webeproben wurde die Konzentration von 1,0 ± 1,0 μmol/l (n=4) und 0,5 ± 0,5 μmol/l (n=4) 
ermittelt. Literaturdaten zur absoluten PpIX-Konzentration in humaner Haut und humanem Bar-
rett-Ösophagus geben eine notwendige Konzentration von ca. 1 - 2 μmol/l bzw. 2 - 9 μmol/l an, 
um eine Gewebereaktion hervorzurufen. Somit ist davon auszugehen, dass eine PDT für vitale 
Grad-IV-Tumoren effektiv ist, während die PDT für Grad-III-Tumore nicht geeignet erscheint. 
Um genauere Aussagen über die infiltrierenden Bereiche treffen zu können, müsste eine Unter-
suchung auf zellulärer Ebene erfolgen. Die in dieser Arbeit verwendete Methode der PpIX-
Konzentrationsbestimmung ist dafür jedoch nicht geeignet. 
Der zweite Teil dieser Arbeit beschäftigt sich mit der Untersuchung der PDT-Wirkung auf 
maligne Gliome in Abhängigkeit von der initialen Photosensibilisatorkonzentration und der Pho-
tobleichung. Ziel der Studie war es, diesen Zusammenhang genauer zu verstehen. 
In einer klinischen Pilotstudie wurden interstitielle PDTs (iPDT) an fünf Patienten mit nicht-
resektablen Glioblastomen multiforme (GBM) nach Gabe von 20 oder 30 mg/kg Körpergewicht 
5-ALA (Gliolan®, medac GmbH, Wedel, Deutschland) durchgeführt. Bei allen Patienten wurde 
jeweils vor und nach der Bestrahlung die In-vivo-PpIX-Fluoreszenz des Gewebes gemessen, um 
xdurch den Vergleich die Photobleichung des Photosensibilisators zu bestimmen. Zusätzlich wur-
den vor der Bestrahlung stereotaktische Biopsien entnommen, von denen ein Teil histologisch 
ausgewertet, und bei einem anderen Teil die absolute Photosensibilisatorkonzentration ex vivo
bestimmt wurde. Die PDT-Wirkung wurde am Tag 1 nach iPDT mittels Magnetresonanztomo-
graphie (MRT) untersucht. Die initiale PpIX-Fluoreszenzintensität, die histologischen Befunde 
und die MRT-Aufnahmen wurden korreliert und alle Parameter mit dem Follow-up verglichen. 
Es konnte gezeigt werden, dass hohe initiale PpIX-Konzentrationen (1,4 - 3,0 μmol/l) und starke 
Photobleichung bei drei Patienten mit einem guten Behandlungsresultat und langer Überlebens-
dauer (29, 30 und 36 Monate) einhergingen. Die Biopsien bei zwei weiteren Patienten wiesen 
geringe PpIX-Konzentrationen (0 - 0,6 μmol/l) auf. Entsprechend konnte vor der iPDT im Ge-
webe keine bzw. eine sehr geringe In-vivo-Fluoreszenz gemessen werden. Übereinstimmend mit 
den Fluoreszenzmessungen blieben gute Behandlungsresultate aus, die Patienten verstarben nach 
3 und 9 Monaten an ihrer Tumorerkrankung. Diese Ergebnisse deuten darauf hin, dass für eine 
erfolgreiche PDT eine Mindestkonzentration an Photosensibilisator im Gewebe vorhanden sein 
muss. Außerdem wurde ein Schritt in Richtung eines anwendbaren impliziten Dosimetriemodells 
für die iPDT gemacht, indem eine einfache und sichere Implementierung zur In-vivo-Messung 
von Fluoreszenz gezeigt wurde. Durch diese Implementierung scheint eine frühe Prognose der 
iPDT-Wirkung möglich zu sein. 
Der dritte Teil dieser Arbeit beschäftigt sich mit der Effektivität der PDT des Cholangiokar-
zinoms (CC) unter Verwendung von niedrig-dosiertem Meso-Tetra-(Hydroxyphenyl-)Chlorin 
(mTHPC, Foscan®, Biolitec pharma Ltd., Dublin, Irland). Literaturdaten zeigen, dass bei Be-
handlung von CCs eine Kombination aus Implantierung von Stents und einer PDT mit dem Pho-
tosensibilisator Porfimer-Natrium (Photofrin®) die Überlebenszeit im Mittel um 265 Tage ver-
längert. Allerdings stellen Nebenwirkungen wie die Photosensibilisierung, die eine Abschirmung 
von direkter Sonnenstrahlung für bis zu drei Monate erfordert, und das Risiko der Perforationen 
von Organwänden durch die PDT Einschränkungen dieses Verfahrens in der palliativen Behand-
lung dieser Erkrankung dar. Ziel dieser Studie war es, die PDT von CCs mit niedrig-dosiertem 
Foscan® zu erforschen, um eine Behandlung mit der Effektivität einer Photofrin®-PDT bei gerin-
geren Nebenwirkungen aufzuzeigen. 
In dieser Studie wurden 14 PDTs an 13 nicht selektionierten, aufeinanderfolgenden Patien-
ten durchgeführt. Foscan®, das in Europa seit 2001 für die palliative PDT-Behandlung von Kopf-
Hals-Karzinomen mit einer Dosis von 0,15 mg/kg Körpergewicht bei 20 J/cm2 und einem DLI 
von 96 Stunden zugelassen ist, wurde mit einer mittleren Dosis von 0,044 ± 0,007 mg/kg Kör-
pergewicht (3 mg/Patient), 50 J/cm und einem DLI zwischen 20 - 72 Stunden durchgeführt. Bei 
5 der 13 Patienten wurde die relative Fluoreszenzintensität unmittelbar vor PDT-Behandlung am 
Tumor und im umgebenden Normalgewebe bestimmt. Bei weiteren 4 der 13 Patienten wurden 
normierte Fluoreszenzkinetiken in der Mundschleimhaut gemessen, um Daten für die Optimie-
rung des DLI zu erhalten. Nach Analyse der Daten wurde das DLI von anfangs 20 auf 67 -
72 Stunden erhöht. Zur Bestimmung des Erfolgs der PDT wurde die Überlebensdauer der PDT-
Patienten nach der Kaplan-Meier-Methode ausgewertet. Zum Zeitpunkt der Auswertung lag die 
Überlebenszeit im Median bei 13 Monaten. Zum selben Zeitpunkt lebten noch 8 der 13 Patien-
ten. Hautirritationen oder schwerwiegendere Komplikationen wie Perforationen der Organwände 
konnten während des Krankenhausaufenthalts nicht beobachtet werden und wurden auch in der 
Folgezeit nicht berichtet. Die Ergebnisse der in dieser Studie durchgeführten 14 PDTs mit redu-
zierter Foscan®-Dosis zeigen die gleiche Wirkung wie eine Photofrin®-PDT – bei gleichzeitig 
reduzierten Nebenwirkungen und Komplikationen. Zusätzlich wurde ein Behandlungsprotokoll 
entwickelt, auf dessen Basis Folgestudien an einem größeren Patientenkollektiv erfolgen können. 
11 Introduction 
The present doctoral thesis is a cumulative thesis and consists of three original manuscripts [1-3]. 
The common aim of the manuscripts is to investigate the feasibility of photodynamic therapy and 
to monitor treatment parameters for therapy optimization. To reach this goal, photosensitizer 
concentration measurements were performed in vivo and ex vivo. In vivo measurements were 
conducted with optical fiber probes whereas for ex vivo measurements, an extraction procedure 
was implemented and fluorescence was measured with a fluorescence spectrometer. Thus, the 
present thesis is an interdisciplinary work, combining physical and chemical methods for better 
understanding the clinical outcome of photodynamic therapy.  
Measurements were performed on two different cancer types, human malignant glioma and 
cholangiocarcinoma, demonstrating the possibility to transfer the results to different organs. The 
detailed approach and the results of these studies are published in the above mentioned manu-
scripts, while background information is given in the following paragraphs of this introduction. 
1.1 Photodynamic diagnosis, fluorescence guided resection
and photodynamic therapy  
Substances which render tissue photosensitive have been known for centuries. They have been 
used for treatment of diseases, e.g. vitiligo, which uses the sun as a source of light for irradiation 
[4]. However, the photodynamic diagnosis (PDD) and therapy (PDT) performed nowadays were 
first established in 1898 when Oscar Raab, student of Hermann von Tappeiner (1847 – 1927), 
noticed the toxic effect on paramecia exposed to acridine when irradiated with light [5]. After 
this discovery, experiments with different substances on enzymes followed [6] and first therapies 
were performed by von Tappeiner et al. in 1903 - 1905 [7, 8]. However, PDD, PDT and related 
procedures such as interstitial PDT (iPDT) and fluorescence guided resection (FGR) are still 
subject of today’s investigations. 
1.1.1 Photodynamic diagnosis 
Photodynamic diagnosis (PDD) is a powerful tool for the intraoperative detection of premalig-
nant lesions and tumors. It relies on the tumor-selective uptake of a fluorescing photosensitizer 
or its precursor. Before treatment, the photosensitizer or precursor is administered to the patient 
either topically, orally or intravenously. After allowing some time for accumulation in the malig-
nant tissue, the region of interest is irradiated by light within the absorption band of the photo-
sensitizer. Most photosensitizers are based on porphyrin or chlorin molecular structures and, 
thus, show similar spectral behavior, e.g. they commonly absorb strongly in the blue spectral 
range (400 - 495 nm). Fluorescence light always experiences a spectral shift to longer wave-
lengths and is, therefore, mostly emitted in the red spectral range (620 - 750 nm), which conse-
quently simplifies the detection of the fluorescence signal. If the fluorescence light is detected 
through a long-pass filter which blocks the blue excitation light not entirely, the tumor will ap-
pear in red and the surrounding normal tissue in blue color, yielding good visual contrast during 
the examination. Such typical “PDD images” are obtained, for instance, for bladder cancer detec-
tion [9] or for fluorescence guided resection of malignant glioma [10].  
1.1.2 Fluorescence guided resection 
During fluorescence guided resection (FGR), the tumor-specific fluorescence is exploited to de-
cide on tissue removal. After administering the photosensitizer systemically, the surgeon can 
resect the tumor layer by layer and is instantly informed through the fluorescence image, whether 
there is any residual tumor tissue left. Since the extent of resection influences the local recur-
2rences, FGR is of particular interest during resection at tumor borders, where in common surgery 
it is often hard to distinguish between tumor and normal tissue. 
Both, the highly specific photosensitizer accumulation and the dependence of recurrences on 
the degree of resection apply to malignant glioma, especially to glioblastoma multiforme (GBM) 
[10-12]. At the same time, the risk of inducing neurological deficits when resecting glioma too 
aggressively is of particular importance [13]. Thus, FGR is a great treatment option for this kind 
of tumor, compared with standard white light surgery. As shown in a phase III study, the rate of 
residual bulk tumor tissue can be reduced applying FGR, and the time to recurrence can be in-
creased compared to standard therapy. However, overall survival could not be improved [14]. 
One difficulty arises for instance when treating infiltrating tumors. For infiltrating tumors the 
tumor cell density decreases at the borders, as does the fluorescence signal. In consequence, the 
measured signal in infiltrating zones is lower than in, e.g., proliferating parts, and might even not 
be detectable at all. Yet, the photosensitizer concentration in the tumor cells of the infiltrating 
zone itself might be the same as for tumor cells in the proliferating part. Hence further investiga-
tions to enhance FGR are necessary, particularly with regard to detecting fluorescence in vivo
more sensitively.
1.1.3 Photodynamic therapy 
Commonly photodynamic therapy (PDT) is used to treat malignant tumors in many different 
organs minimally invasively [15], but it can also be applied to non-oncological diseases, such as 
acne and warts [16, 17]. 
Like PDD and FGR, PDT is performed in two steps. In the first step, the photosensitizer is 
administered, and in the second step, it is activated by irradiation with light within its absorption 
band. After excitation from the ground state into the first excited singlet state, as illustrated in the 
Jablonski diagram in Figure 1, the electrons can either undergo relaxation directly into the 
ground state via internal conversion or via emission of a fluorescence photon. Alternatively, they 
can be transferred into a triplet state via inter-system crossing. As the relaxation from the triplet 
state to the ground state – via internal conversion or phosphorescence – is a slow process, there 
is a significant probability for energy transfer to other molecules. Through this energy transfer, 
reactive oxygen species or singlet oxygen may be produced, which in turn induce the cytotoxic 
reaction in PDT, referred to as type I and type II reactions, respectively [18]. Since the PDT  
effect is initiated by the electrons in the triplet state, a high triplet quantum yield is desirable for 
photosensitizers used during PDT. 
Singlet oxygen diffuses only about 0.01 - 0.02 μm in tissue [8], and consequently oxidized 
molecules are induced close to the location of the photosensitizer. The details of the cell death 
mechanism thus depend strongly on the intracellular distribution of the photosensitizer. Most 
photosensitizers accumulate in the cell membrane or membranes of organelles, for instance the 
Golgi apparatus, lysosomes, endoplasmic reticulum or mitochondria [19]. In consequence, the 
cells die either via necrosis due to cell membrane damage or vessel collapse, or via apoptosis 
induced by damage of organelle membranes [20]. 
Regardless of the cell death mechanism, PDT is primarily a local therapy. The radical for-
mation takes place in proximity of the selectively accumulated photosensitizer and is restricted to 
the irradiated tissue volume. This is caused by the limited penetration depth of light into tissue of 
about 1 mm to 1 cm in the visible spectral range. However, the limited penetration depth of light 
in tissue can also be a restriction for PDT of tumors in deeper tissue regions. Therefore, light in 
the red spectral range is preferentially used for irradiation as it typically propagates deeper into 
the tissue, although a lower absorption coefficient of most photosensitizers has to be accepted in 
this spectral range. Consequently, the therapeutic penetration depth, referred to as the distance 
between radiation entrance into tissue and depth of the resulting necrosis, is larger for red com-
pared to blue excitation light. 
3In addition to the local effect, PDT also induces an immune response, which is described fur-
ther in [21, 22].
Figure 1. Jablonski diagram of PDT reaction 
Another main feature of PDT, apart from the possibility of local treatment and the immuno-
PDT, is the possibility to repetitively treat patients. As mentioned before, most photosensitizers 
accumulate in the cell membranes. Only very few accumulate in the nucleus [4, 23], for which 
reason the DNA stays intact. In contrast, in radiotherapy as a standard treatment, healthy tissue 
surrounding the tumor is unavoidably exposed to the irradiation. As a result the DNA of normal 
cells can be affected and radiotherapy can only be performed until a threshold dose is reached. 
This threshold dose is attempted to be minimized by applying multileaf collimators and by irra-
diating from many different angles. Chemotherapy as another standard treatment can result in 
resistance of tumor cells and is also, when administered systemically, not highly selective. It 
affects all rapidly dividing cells, resulting, for instance, in bone marrow suppression. PDT, how-
ever, can be minimally toxic for the surrounding normal tissue when the correct photosensitizer 
is used and light is applied locally. Ideally, photosensitizers only accumulate in tumor cells, and 
healthy cells are not treated at all as the light alone does not cause any tissue damage. However, 
such an ideal photosensitizer has not been found yet and, in addition, endogenous photosensitiz-
ers can be excited at the wavelength of the applied photosensitizer, resulting in treatment of 
healthy cells. In order to conduct PDT, light needs to be delivered to the target tissue. Different 
approaches of light delivery exist, depending on the treatment site. In case of treatment of skin 
diseases, light is applied without the use of sophisticated optical devices, while lesions in hollow 
organs can be irradiated via fibers introduced through the working channel of an endoscope. 
Therefore, PDT of cholangiocarcinoma, for example, can be performed during the commonly 
performed endoscopic retrograde cholangiopancreatography (ERCP) for replacement of stents. If 
PDT is not only performed on a superficial lesion but in a larger volume, light can be applied 
through diffusors connected to light transmitting fibers which are inserted into the tissue itself. 
This treatment is called interstitial PDT (iPDT) [24, 25].
The outcome of PDT, however, depends on the same parameters for all treatment approach-
es. Important parameters are the photosensitizer concentration, the applied light dose, the oxygen 
concentration in the target tissue and the drug-light interval (DLI), defined as the time between 
photosensitizer application and irradiation. This thesis concentrates on the photosensitizer con-
centration and the DLI. 
When regarding the photosensitizer concentration, it has to be kept in mind that the efficacy 
of the photosensitizer does not depend on the concentration alone, but also on its photophysical 
parameters, i.e. its extinction coefficient and triplet quantum yield. If the photosensitizer concen-
tration at the treatment site is known, the light dose can be adjusted accordingly. A lower singlet 
oxygen induction because of a lower photosensitizer concentration can be compensated by a 
higher light dose and vice versa. Nonetheless, if no photosensitizer is present, singlet oxygen 
4cannot be induced, for which reason a threshold photosensitizer concentration for effective PDT 
must be present. The same is true for molecular oxygen in the target tissue, which is required for 
the formation of singlet oxygen. Measurements of oxygen concentrations are also a subject of 
current investigations [26], but they are not addressed in the present thesis. 
In the third study of this thesis, the DLI is assessed. The DLI strongly depends on the specific 
photosensitizer, its application form and its pharmacokinetics in the human body. Commonly, 
photosensitizer pharmacokinetics differ in plasma, normal and tumor tissue. Therefore, the con-
trast of fluorescence light emission between normal and tumor tissue varies with time, which is 
called transient selectivity. In addition, the point in time for maximal photosensitizer concentra-
tion in a tumor does not necessarily correlate with the point of maximal contrast. The DLI can 
thus be chosen based upon different assumptions. It can either be the time interval between drug 
administration and highest fluorescence contrast between the tumor site and the surrounding 
normal tissue, greatest photosensitizer accumulation in plasma or greatest photosensitizer accu-
mulation in the tumor tissue [27-29]. Ideally, the point in time of maximal photosensitizer con-
centration in the tumor is chosen to maximize the PDT effect. However, if the contrast between 
tumor and normal tissue is not high at that time, a different point in time with a better contrast 
might be preferable. Naturally, the choice between a good contrast and high photosensitizer con-
centration also depends on the targeted organ. In case of brain malignancies, for example,  
harming normal tissue during treatment may result in stronger side effects than during bladder or 
skin treatments. Accordingly, a higher contrast rather than a maximal photosensitizer concentra-
tion would be preferable for brain malignancies. Nevertheless, when administering a low photo-
sensitizer dose, treatment at maximal photosensitizer concentration might be favorable over a 
good contrast. The time differences between time of greatest contrast and time of highest photo-
sensitizer concentration may amount to several hours or even days. Regardless of the strategy 
according to which the DLI is chosen, DLIs of commonly used photosensitizers range from a 
few hours, as in the case of 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX (PpIX), 
up to several days, for instance in case of temoporfin [19]. In order to determine these times, 
pharmacokinetics can be assessed by monitoring the relative fluorescence intensity at the same 
tissue site. This is possible because in this case, the fluorescence intensity strongly depends on 
the photosensitizer concentration, due to only small variations in time of the optical parameters, 
i.e. absorption and scattering. However, when trying to derive absolute photosensitizer concen-
trations from the fluorescence measurements, the varying optical parameters have to be  
considered, as described in section 1.3. 
1.2 Photosensitizers 
A variety of classes of photosensitizers exists. For each class, different drugs are commercially 
available, showing different pharmacological, chemical and photophysical behavior. Which pho-
tosensitizer is suited best depends on the targeted organ. Nevertheless, for all photosensitizers,
high target selectivity, high absorbance at long wavelengths, fast pharmacokinetics and especial-
ly high reactivity are desired. A high reactivity is achieved by a high triplet state quantum yield 
and a high life time. 
Hence most photosensitizers are alike in their basic structure, possessing an aromatic ring 
which causes the fluorescence when the photosensitizer is excited. The main differences between 
photosensitizers arise from the central metal ion in the main aromatic ring and the chemical 
composition of the side chains. These side chains also determine the intrinsic characteristics of a 
photosensitizer, e.g. their lipophilicity – in other words, whether a photosensitizer can penetrate a 
cell membrane easily. Consequently, it also determines the intracellular localization. Another 
significant influence on the localization is given by the route of administration of the photosensi-
tizer. Some photosensitizers can be applied topically or systemically, but in most cases one ap-
plication route is preferable. By applying it directly to the treatment region, e.g. topically when 
treating skin lesions, an inherent selectivity is given. But also by choosing a drug light interval 
5with a high contrast between tumor and normal tissue, as described above, the selectivity can be 
enhanced.
In the studies of this thesis, 5-ALA-induced PpIX was applied for treatment of malignant gli-
oma while meso-tetrahydroxyphenyl chlorine (mTHPC, Foscan®) with the generic name temo-
porfin was used for PDT of cholangiocarcinoma. However, purified hematoporphyrin derivative 
(HPD, Photofrin®) is commonly used for PDT of cholangiocarcinoma instead of mTHPC, for 
which reason all three are described in more detail in the following paragraphs. 
1.2.1 Protoporphyrin IX 
Protoporphyrin IX (PpIX) is part of the heme biosynthesis pathway, in which 5-ALA is formed 
into porphobilinogen and uroporphyrinogen III before protoporphyrinogen IX and finally PpIX 
is synthesized [30]. In a last step, a ferrous ion (Fe++) is inserted into the porphyrin ring by the 
enzyme ferrochelatase to form heme. The chemical structures of 5-ALA and PpIX are shown in 
Figure 2a and 2b. Since almost all cells of the human body synthesize heme, PpIX is also present 
within these cells and not only in tumor cells. Nevertheless, when exogenous 5-ALA is adminis-
tered before treatment, it can be observed that PpIX accumulates selectively in tumor cells. The 
main reason is believed to be a reduced activity of ferrochelatase [31, 32] and, for some tumors, 
a more active porphobilinogen deaminase, which catalyses the formation of uroporphyrinogen 
from porphobilinogen [33]. In addition, the selectivity is increased by the hydrophilic characte- 
ristics of 5-ALA, for which it cannot penetrate healthy skin or membranes easily. Tumorous skin 
and tissue layers, however, show an increased permeability, which permits 5-ALA to pass into 
deeper tissue layers [34]. Nevertheless, the penetration depth of 5-ALA remains limited, why 
deeper lying or thicker lesions are difficult to treat. In order to elude this problem, different lipo-
philic derivatives of 5-ALA have been examined [35, 36]. 
Figure 2. Chemical structures of a) 5-aminolevulinic acid, b) protoporphyrin IX and c) temoporfin 
Also, apart from the limited penetration depth of 5-ALA itself, the limited penetration depth 
of the excitation light restricts the achievable treatment depth. PpIX has one main absorption 
band at 412 nm, the Soret band, and four smaller vibrational Q-bands at around 508 nm, 541 nm, 
580 nm and 635 nm in tissue. For typical “PDD images”, the absorption band at 412 nm is used, 
yielding high contrast albeit limited penetration depth. Also, for some treatments, the limited 
optical penetration depth is desirable, e.g. PDT of actinic keratosis is performed with blue light, 
in order to intentionally keep the therapeutic penetration depth minimal [37]. Most often, howev-
er, the absorption band at 635 nm is exploited for PDT. 
A great advantage in using PpIX for PDT is its rapid pharmacokinetics. The concentration of 
PpIX in tumor peaks at about 1 - 6 h after administration of ALA, depending on the lesion, and 
6the patients are photosensitive only for about 24 h [30, 38]. Thus, the risk of side effects such as 
skin burns is low and patients can be exposed to light shortly after treatment, which is a great 
advantage for the patient, especially when PDT is used for palliative treatment. For skin lesions, 
PDT with PpIX can even be performed in an outpatient setting.  
Clinically approved indications for ALA or its derivatives are PDT for actinic keratosis and 
basal cell carcinoma (BCC), as well as PDD for bladder cancer and FGR for malignant glioma. 
Also, experimental clinical applications of ALA and its derivatives have been reported for PDT 
of bladder and PDD and iPDT of prostate cancer [39-41], as well as for PDT and iPDT of brain 
tumors [25]. In case of skin cancer, ALA can be applied in form of an ointment. In case of blad-
der cancer, ALA is instilled intravesically or, for deeper lying lesions, administered systemically. 
When performing FGR, PDT or iPDT of brain tumors, ALA is delivered orally in a drinking 
solution. Although it is administered systemically for treatment of malignant glioma, PpIX ac-
cumulates highly selectively in the tumor volume. A main reason for this selectivity is the blood 
brain barrier. ALA cannot penetrate the intact blood brain barrier, but in brain tumors there are 
fewer tight junction molecules, i.e. claudins and occludins, for which reason the barrier is more 
permeable for ALA [42, 43]. In the first and second study of this thesis, 5-ALA (Gliolan®,
medac GmbH, Wedel, Germany) was used, as precursor of PpIX, for treatment of malignant 
glioma at the approved dose of 20 mg/kg b. w. 
1.2.2 Porfimer sodium 
Porfimer sodium, approved in 1993 in Canada, was the first photosensitizer to be approved for 
PDT (Photofrin®, Axcan Pharma Inc., Mont-Saint-Hilaire, Canada). It is the purified part of 
hematoporphyrin derivative (HpD) and consists of up to eight porphyrin rings, although its exact 
composition has still not been determined. Due to the Soret band and Q-bands of the porphyrin 
ring structure, it can be excited, just like other porphyrin-based photosensitizers, at a number of 
wavelengths between 400 and 650 nm [44]. However, for PDT, the absorption band at 630 nm is 
commonly used because it favors the optical penetration depth over the absorption probability.  
Porfimer sodium is commonly administered intravenously and has been shown to be selec-
tive and effective in several tumor models [45]. Today, it is still frequently used for PDT, espe-
cially for treatment of cholangiocarcinoma, although it has also been shown that at the common-
ly administered dose of 2 mg/kg b. w., it is not very selective, and the absorbance at the red spec-
tral range is low [19]. Yet, when staying out of strong sunlight, only light erythema are reported 
in addition to side effects specific to the treated organ. After PDT of cholangiocarcinoma, to 
name one example, mild constipation, coughing, nausea, pain and swelling at injection site, 
mood changes, fever and tachycardia may occur [46].  
Compared to 5-ALA, porfimer sodium has a long DLI of 40 - 50 h. Another drawback is the 
pronounced and long-lasting photosensitization of skin for 4 - 12 weeks [8], restricting the pa-
tients’ quality of life immensely because they have to shield from direct sunlight during this 
time. However, compared to 5-ALA it is suitable, for instance, for treatment of cholangiocarci-
noma because of its higher penetration depth. 
1.2.3 Temoporfin 
Meso-tetrahydroxyphenyl chlorin (mTHPC, temoporfin) is a single pure chlorine compound and 
a potent photosensitizer. Its chemical structure is shown in Figure 2c. The phototoxicity of temo-
porfin exceeds the phototoxicity of porfimer sodium by about a factor of 100 - 200 [19, 47]. In 
addition, temoporfin is excited at 652 nm, where the penetration of light into tissue is significant-
ly higher than at 630 - 635 nm. The therapeutic penetration depth of temoporfin, including light 
penetration depth and diffusion constant, has been reported to be up to 9 mm [48] for PDT of 
cholangiocarcinoma, while the therapeutic penetration depths of PpIX and porfimer sodium have 
been reported to be only 2 and 4 - 6 mm, respectively [46, 49]. 
7Temoporfin is approved for head and neck PDT with the trade name Foscan® (Biolitec 
pharma Ltd., Dublin, Ireland). It is commonly applied intravenously, together with a lipid emul-
sion to induce a better distribution. In human plasma, the concentration decreases with half-lives 
reported to be about 40 and 45 h [50, 51], whereas the concentration in tissue is lower than in the 
vascular system at first. Then it rises above it before it decreases again. For squamous-cell carci-
noma at three different stages, it could be shown that the concentration peak measured in the 
tumor tissue appears before the peak in normal tissue (about 30 - 70 h versus 60 - 90 h) [52]. As 
is true for other photosensitizers as well, its localization and its contrast in tissue depend on time. 
Therefore, the balance between either vascular or tissue damage can be adjusted by choosing the 
appropriate DLI, as has been proven in clinical treatment [29, 53]. The determination of the ideal 
DLI, however, is still a subject of present research. The DLI for the clinically approved indica-
tions is 96 h (at 0.15 mg/kg b. w. i.v.), accordingly, direct tissue damage is induced during PDT. 
In literature, one study can be found in which temoporfin is applied for PDT of cholangiocarci-
noma at a dose of 0.15 mg/kg b. w. However, side effects such as cholangitis and haemobilia had 
to be reported, which resulted in one death [54]. In the third manuscript of this thesis, temoporfin 
was used at low doses (0.032 - 0.063 mg/kg b. w.) in order to reduce side effects. Doses were 
chosen on the basis of a study performed by Betz et al. The study describes how, in case of basal 
cell carcinoma PDT, good results were achieved in a similar dose range (0.03 - 0.05 mg/kg b. w.) 
with DLIs ranging from as low as 1 - 48 h [55]. Based on this publication, a DLI of 20 h was 
chosen for the study of this thesis. The contrast at such a short DLI is still low, but because of the 
low dose, a low contrast was assumed to be sufficient to avoid damage to the surrounding normal 
tissue. However, after five patients had been treated, no contrast could be determined at all. At 
the same time, pharmacokinetics measurements conducted on oral tissue indicated maximal pho-
tosensitizer concentrations at 60 - 120 h after drug application. For both reasons, the DLI was 
changed for the following patients to 67 - 72 h. Although the chosen DLI for temoporfin is long-
er than the DLI for porfimer sodium, the complete duration of systemic photosensitization is less 
than two weeks and thus considerably shorter [29]. 
1.3 Photosensitizer concentration measurements 
The photosensitizer uptake is strongly patient dependent. Thus, the concentration in tissue cannot 
be determined by regarding the applied dose alone. In addition, to optimize treatment, the con-
centration has to be measured, ideally in vivo before and during treatment. Many approaches to 
determine the absolute concentration are based on fluorescence measurements. However, the 
optical properties, i.e. absorption and scattering, have an important impact on the measured fluo-
rescence spectra, preventing a direct correlation of measured fluorescence intensity to photosen-
sitizer concentration. An exception would be an infinitesimal small single bare fiber, explained 
below, which, however, would not be suitable for collecting enough fluorescence photons for a 
sufficient signal to noise ratio. Therefore, the optical properties of tissue have to be considered to 
be able to correct the measured fluorescence spectra to obtain the so-called intrinsic fluorescence 
spectrum, which matches a fluorescence spectrum measured in a clear solution, i.e. measured 
without interference of scattering or absorption. Consequently, it can be calibrated to indicate the 
absolute photosensitizer concentration value. Direct and indirect approaches of determining opti-
cal properties [56] ex vivo as well as in vivo and accordingly the intrinsic fluorescence spectra 
have been investigated for more than 20 years, but are still subject of current research. In all 
three studies of the present thesis, relative and absolute photosensitizer concentrations were 
measured in vivo and ex vivo, respectively. 
For the first study of this thesis, the absolute photosensitizer concentration was measured ex
vivo with a fluorescence spectrometer after extraction of the photosensitizer from tumor biopsies. 
Other determination methods of the photosensitizer concentration are based on optical fiber set-
ups, with the intention of being usable in vivo, for instance through endoscopes. In order to com-
pensate for the interference of variable optical tissue parameters, they either include remission 
8measurements and correction algorithms [57-59], or use fiber geometries with a low sensitivity 
to the optical parameters of the tissue. The simplest approach is to use a single optical bare fiber 
for measurements [60, 61]. When the mean free path of the excitation and fluorescence light is 
large compared to the fiber diameter, the influences of the optical parameters of the tissue on the 
fluorescence measurements are low. A comparison of four different approaches has been per-
formed and published by the author of this thesis [62]. Based on these results, a single optical 
fiber measurement approach was chosen for the in vivo fluorescence measurements in the second 
publication of this thesis. Though other, more complicated, probe geometries deliver better re-
sults, using a single optical fiber as a probe simplifies the set-up enormously, while still allowing 
to receive useful data. The raw fluorescence spectra were, accordingly, correlated to the photo-
sensitizer concentration present in tissue. 
1.4 Photobleaching as dosimetry model 
Photobleaching has to be taken into account when determining the photosensitizer concentration. 
While the photosensitizer is irradiated, it can be inactivated due to conformational changes called 
photobleaching, which result in a permanent decrease in fluorescence intensity. These molecular 
changes arise when the excited photosensitizer reacts with the surrounding media, mainly by 
oxidization. Therefore, photobleaching depends on the irradiation light dose and the present 
oxygen concentration [63]. Due to this dependence on the oxygen concentration, it is not possi-
ble to increase photobleaching and, consequently, the PDT effect, by simply increasing the light 
intensity. The light intensity needs to be chosen in relation to the oxygen present in tissue and the 
diffusion constant. Therefore, when tissue containing a photosensitizer is exposed to light in an 
uncontrolled way prior to measuring the fluorescence, the initial photosensitizer concentration 
can no longer be derived reliably. However, when irradiation is controlled, photobleaching can 
also be used for PDT dosimetry. 
Dosimetry models in PDT try to evaluate the tissue damage induced during PDT from dif-
ferent parameters. In order to monitor and individualize treatment, different dosimetry models 
can be applied. As mentioned above, the outcome of PDT depends on different parameters, i.e. 
photosensitizer concentration, oxygen concentration, light dose and the DLI. If each parameter is 
monitored separately, the dosimetry model is called an explicit model. Another monitoring ap-
proach is the direct dosimetry model, for which the concentration of singlet oxygen that is re-
sponsible for cellular damage is directly measured. A third approach, called implicit dosimetry 
model, is to monitor the bleaching kinetics as an indicator for the PDT-induced singlet-oxygen 
production. This dosimetry model is based on the assumption that PDT induced singlet oxygen 
causes not only tissue damage but the photodegradation of the photosensitizer as well. In that 
case, the bleaching kinetics implicitly contains information on the relative PDT dose [64]. Alt-
hough these different dosimetry models are proposed and researched, there is still no gold stand-
ard for monitoring and realizing patient dependent treatment. 
In the second study of this thesis, an approach towards an implicit dosimetry model based on 
photobleaching was investigated in a pilot study of iPDT. The relative fluorescence intensity was 
measured before and after iPDT of GBMs with the same set-up used for treatment. After the flu-
orescence intensities before and after treatment were compared, the relative bleaching rate could 
be determined, gaining information about the treatment itself. Moreover, the results of the pilot 
study suggest that the measurement of the fluorescence kinetics is suitable as an early treatment 
prognosis, as was also speculated by Pogue et al. [65]. Fluorescence measurements could be em-
ployed easily and were shown to be safe. 
Naturally, for realizing a true implicit dosimetry model, the initial absolute photosensitizer 
concentration needs to be known. In that case, the PDT effect could be predicted even more pre-
cisely, and patient specific treatment would be possible. This encourages further investigations to 
determine the absolute photosensitizer concentration in vivo.
91.5 Glioma 
The age standardized incidence rate in 2008 for primary tumors of the central nervous system 
(ICD-10 Code C70 - C72) in the developed part of the world amounts to 6.0 for men and 4.4 for 
women per 100,000 [66]. In Germany, the incidence was even higher with 7.7 and 5.3 per 
100,000 [67]. About 30% of all primary tumors of the central nervous system are categorized as 
glioma, while, when focusing on malignant brain tumors, glioma make up even 80% [68]. 
Named are glioma after their origin – they arise from the glial cells – and categorized by their 
location, cell type and grade. Commonly, grading is conducted via the WHO classification 
scheme based on histopathology, dividing gliomas into grade I - IV. Treatment procedures are 
chosen based on the grades. Therefore, sampling remains indispensable [69], although diagnosis 
of tumors of the central nervous system is commonly achieved by MRI [70-72]. Biopsies can 
either be taken via a stereotactic approach or during the resection surgery. 
In the WHO classification, gliomas which are not infiltrating and proliferating slowly are 
classified as grade I, having a high probability of a cure after resection, whereas grade IV tumors 
are the most lethal tumors. Grade IV tumors are related to a fast progress of the disease, before 
and after treatment. Often, necrotic tissue is found in the central part. Unfortunately, the most 
common gliomas in adults are grade IV glioblastoma multiforme (GBM) as demonstrated with 
data taken during 2005 - 2009 in the USA, which make up 15.8% of all primary tumors of the 
brain and central nervous system and even 54% of all gliomas [73]. Data from 1992 - 1997 in the 
USA show the highest yearly incidence of all gliomas for glioblastoma multiforme with 2.96 per 
100,000 compared to the next highest incidence of 0.49 per 100,000 for grade III anaplastic as-
trocytoma, yielding a 5-year survival expectancy of less than 3% [74]. Even the two-year surviv-
al expectancy of GBMs was as low as 8% and the one-year survival resulted to 28%. This hardly 
changed over the years, given a 5-year survival rate of 5% for data acquired in the USA from 
2004 - 2007 [68]. 
In order to make a prognosis on survival time, however, the location of the tumor and, of course, 
the patient’s general condition and age have to be taken into account in addition to the grading. 
Nevertheless, published data from the USA state 5-year survival rates of about 90 - 100% for 
grade I [74], 50 - 80% for grade II and 30 - 80% for grade III gliomas [68], depending on the 
exact tumor type. 
Currently, glioma patients are commonly treated by open tumor resection and fractionated 
radiotherapy with concomitant and adjuvant temozolomide. Especially for patients with methyl-
ated promoter O(6)-methylguanine-DNA methyltransferase (MGMT), the survival time was in-
creased with the introduction of temozolomide [75]. Thus, the promoter status is in addition to 
the already mentioned location of the tumor and the condition and age of the patient, an im-
portant factor to predict survival time. The decision on the exact treatment procedure, however, 
is usually personalized and decided on case by case [76]. 
An additional, promising but still experimental, treatment is PDT. PDT of glioma was not yet 
applied as stand-alone therapy, but as adjuvant therapy together with resection by postsurgical 
irradiation of the resection cavity, or as iPDT treatment of selected tumors (e.g. small in size, no 
infiltration of the corpus callosum, no infiltration of the ventricle) in case a resection is not pos-
sible. Theoretically, not only small glioma can be treated with iPDT, but the limited penetration 
depth of light in tissue requires a high density of fibers, which limits the feasibility.  
As described in chapter 1.3.3, ideally the PDT and also the iPDT is a minimal invasive 
treatment form. However, major complications could result from iPDT of glioma, depending on 
the volume and the location of the tumor, as well as the photosensitizer used. 
In the first study [1] of this thesis, basic research was conducted on the concentration of PpIX 
in suspected grade IV tumors. For this study, tissue samples were acquired during FGR per-
formed after administration of 5-ALA. PpIX concentrations were highest in vital grade IV tu-
mors with 5.8 ± 4.8 μmol/l measured for 8 patients. The concentration was significantly higher 
compared to grade III tumors (0.2 ± 0.4 μmol/l), which were determined in another four patients. 
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What is more, a high variation in the amount of photosensitizer within a single grade IV tumor 
could be determined. For infiltrating zones as well as necrotic tissue, PpIX levels were much 
lower than in the solid tumor. Therefore, it needs to be investigated further whether PDT is ap-
plicable for infiltrating tumors and tumors containing necrotic tissue.  
Another potential improvement in glioma diagnosis that could be derived from the results of 
this study is the guidance of stereotactic biopsy sampling. A fiber probe measuring the absolute 
PpIX concentration could indicate whether the probe tip is in normal tissue, the infiltrating zone, 
necrotic tissue or the vital part of the tumor. Thus, surgeons could identify the location from 
which to take a relevant tissue sample. During an interdisciplinary project in which the author 
took part, potential fiber probe and endoscope set-ups were evaluated and a method to exploit the 
fluorescence of a second fluorophore to detect vessels was developed and published [62, 77, 78]. 
However, further research in this area is necessary to verify its reliability. 
The contribution of Gesa Kniebühler to this study was to determine the PpIX concentra-
tion and to perform the analysis of the spectra, together with Ann Johansson. Determining 
the PpIX concentration included the extraction of PpIX and measurements of fluorescence 
with a fluorescence spectrometer.  
The second manuscript of this thesis comprises results of investigations on the use of PpIX for 
iPDT [2], parts of which were also presented at the Photonics Europe conference [79]. Aim of 
the study was to investigate the dependence of the PpIX concentration on the treatment outcome. 
Through in vivo fiber based measurements of the fluorescence intensity before and after PDT, ex
vivo absolute concentration measurements and MRI it could be shown that the treatment out-
come depends on the PpIX concentration in the tumor. Moreover, it seems possible to easily im-
plement a safe method to determine the presence and bleaching of photosensitizer and therefore 
achieve an early treatment outcome prognosis. 
The contribution of Gesa Kniebühler to this study was to determine the PpIX concentra-
tion of the biopsies. This involved performing the extraction procedure and the measure-
ments of the PpIX fluorescence with a fluorescence spectrometer.
1.6 Cholangiocarcinoma 
Cholangiocarcinomas (CCs) are malignant tumors of the bile duct. About one third of CCs are 
localized within the liver and about two third arise within the perihilar region, involving the 
common bile duct and/or the hepatic ducts. 
The yearly incidence rate of CCs in the western world is about 3 - 5 per 100,000 [80]. Since 
they are highly lethal, refraining from treatment results in a median survival time of only about 
three months. Therefore, investigations on improving treatments are of great importance. To-
gether with carcinomas of the gallbladder, CCs account for 2% of all malignant tumors [81]. The 
only curative treatment for patients with CCs is the complete resection (R0) [82]. However, a 
complete resection is, at time of diagnosis, possible for only about one third of the patients [83]. 
A reason for this and, consequently, the high mortality rate is that at the time of diagnosis, CCs 
are often in an advanced state. This means that the tumor can either be too large, or metastases 
can be present already. Lymph node metastases are present in about 30 -50% of cases at time of 
diagnosis, while distant metastases occur in less than 20% of patients. Metastases of CCs have 
been found in lymph nodes, liver, lung, skin and bones as well as in the peritoneum [84, 85]. As 
a result, the five-year survival time for the most common (60%) hilar CC has been reported to be 
only about 30% for patients who underwent R0 resection, and 0% for patients with partial (R2) 
or no resection [86, 87]. 
In order to enable a decision about a treatment procedure, perihilar CCs are often classified 
further according to the pattern of the involvement of the hepatic duct bifurcation. First intro-
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duced by Bismuth and Corlette, the advanced classification scheme is shown in Figure 3 [88-90]. 
If the bifurcation is affected (hilar CC), the tumor is considered a Klatskin tumor, which is the 
case for Bismuth type II - IV. Since the stages are defined depending on the tumor location, they 
consequently indicate to a great part the possibility of resection of the tumor. Hence, the ex-
pected survival time may also be estimated based on the Bismuth type. For Bismuth type IV, 
however, a complete resection is not possible. Although staging of CCs via the Bismuth classifi-
cation is common practice, Zervos et al. [91] could not find a significant correlation between 
stage and survival time for any of the different staging systems. Thus, they suggest that an ag-
gressive resection should be performed for any stage of CC.  
Figure 3. Bismuth classification of CCs. Grey parts indicate tumor location 
A different approach is a palliative treatment, especially because of the estimated low  
survival times for extended resections with positive margins left and a rate of death after surgery 
of 10% [86, 92]. Common treatments for non-resectable CCs are biliary endoprosthesis, chemo-
therapy and radiation therapy. In the last few years, photodynamic therapy (PDT) also gained in 
importance. While the implantation of stents results in a median survival time of six months after 
diagnosis, stenting can easily be combined with PDT, which results in a median survival of 12 
months for retrospective studies [93]. In a meta-analysis of six prospective studies [94], the me-
dian survival for stenting alone could be prolonged by 265 days on average. Photofrin® is com-
monly used for PDT of CCs. However, when using Photofrin®, patients remain photosensitive 
and require shielding from sunlight for up to three months. This is a great disadvantage, especial-
ly in view of the treatment being palliative. What is more, there have been reports of complica-
tions such as organ wall perforations. In order to maintain a good clinical outcome while  
reducing the side effects and, most importantly, shortening the period of photosensitivity, the use 
of temoporfin (Foscan®) at a low dose has been investigated in the third manuscript [3] of the 
present thesis. For this study, 13 patients with CCs of all Bismuth types, for which a complete 
resection was no longer possible, were treated in 14 PDT sessions and the survival time until 
publication was analyzed. Apart from performing the treatment and evaluating the outcome, flu-
orescence measurements were performed to find the optimal DLI and suggest an optimized 
treatment protocol. 
The contribution of Gesa Kniebühler to this study was to perform the contrast fluorescence 
measurements during ERCP as well as the fluorescence kinetics measurements together 
with Thomas Pongratz. She also evaluated the data and wrote the manuscript.  
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ABSTRACT
Protoporphyrin IX (PpIX) produced from exogenous, orally
administered 5-aminolevulinic acid (ALA) displays high tumor-
selective uptake and is being successfully employed for ﬂuores-
cence-guided resection (FGR) of human malignant gliomas.
Furthermore, the phototoxicity of PpIX can be utilized for
photodynamic therapy (PDT) of brain tumors, which has been
shown previously. Here, the absolute PpIX concentration in
human brain tissue was investigated following oral ALA
administration (20 mg kg)1 b.w.). An extraction procedure was
used to quantify PpIX in macroscopic tissue samples, weighing
0.013–0.214 g, obtained during FGR. The PpIX concentration
was signiﬁcantly higher in vital grade IV tumors (5.8 ± 4.8 lM,
mean ± SD, range 0–28.2 lM, n = 8) as compared with grade
III tumors (0.2 ± 0.4 lM, mean ± SD, range 0–0.9 lM,
n = 4). There was also a large heterogeneity within grade IV
tumors with PpIX displaying signiﬁcantly lower levels in
inﬁltration zones and necrotic regions as compared with vital
tumor parts. The average PpIX concentration in vital grade IV
tumor parts was in the range previously shown sufﬁcient for
PDT-induced tissue damage following irradiation. However, the
feasibility of PDT for grade III brain tumors and for grade IV
brain tumors displaying mainly necrotic tissue areas without
solid tumor parts needs to be further investigated.
INTRODUCTION
Gliomas account for more than 70% of primary brain tumors
(1). High-grade gliomas include WHO grade III tumors such
as anaplastic astrocytoma (AA), anaplastic oligodendroglioma
(AO), anaplastic oligoastrocytoma (AOA), anaplastic ganglio-
glioma (AG) and tumors of WHO grade IV such as glioblas-
toma multiforme (GBM) and gliosarcoma (GS). Conventional
treatment options include surgery, radiation therapy and
chemotherapy. These tumors always inﬁltrate the adjacent
normal brain in a diffuse way (2,3), making it nearly
impossible to visualize tumor borders and to surgically remove
all vital tumor regions. Furthermore, glioma cells are at least
partially resistant to radiation and chemotherapy (4). Hence,
recurrences are unavoidable and median survival limited, e.g.
2-year survival rates of 43% and 3–8% for AA and GBM,
respectively (1).
5-aminolevulinic acid (ALA) is a photosensitizer precursor
that is converted into the actual photosensitizer, protopor-
phyrin IX (PpIX), as a part of the endogenous heme-cycle (5).
PpIX generally displays a high tumor-selective uptake (in the
range of 50:1 for the case of malignant brain tissue [6]),
explained by differences in enzymatic activity in tumor cells as
compared with normal tissue (7–9) plus a limited ability of
ALA to penetrate an intact blood–brain barrier (10). The use
of ALA for ﬂuorescence-guided resection (FGR) has been
demonstrated to be not only helpful for a better detection and
delineation of vital tumor tissue from the inﬁltration zone and
nonneoplastic brain, but has also improved the progression-
free survival in patients with malignant gliomas as compared
with surgery performed under white-light alone (65% versus
36% complete resection and 41% versus 21% 6-month
progression-free survival) (11). In 2007, the use of ALA
(Gliolan; medac GmbH, Wedel, Germany) at a dose of
20 mg kg)1 b.w. acquired clinical approval in the European
Union for FGR of residual glioma. Recently, the potential of
ALA-mediated FGR for visualizing anaplastic foci also in
diffusely inﬁltrating gliomas without signiﬁcant contrast
enhancement on magnetic resonance has been shown (12).
PpIX also displays phototoxic effects, which are exploited
for photodynamic therapy (PDT) in different organs, including
brain tumors (13–16). Irradiation, e.g. at 635 nm, leads to
excitation of PpIX and the subsequent formation of singlet
oxygen and reactive oxygen species, which in turn causes
cellular damage. Median survival following ALA-mediated
brain-PDT of 15 months has been reported (13,17) and
evidence exists for some intriguing long-term survivors
(>5 years) (18). Factors that might inﬂuence the treatment
outcome are the patient-speciﬁc light (19,20) and photosensi-
tizer distribution (6,21), the oxygenation status of the target
tissue (22) as well as the synergistic effects of PDT and a
treatment-induced immune response (23). For example,
employing hematoporphyrin derivative (HpD) for PDT of
GBM, higher photosensitizer uptake was associated with
improved clinical outcome (21).
For FGR and brain-PDT, the PpIX uptake has mostly been
investigated by means of its characteristic ﬂuorescence (6,24).
However, as ﬂuorescence signals are inherently sensitive to the
optical properties, i.e. the absorption and scattering coefﬁ-
cients, of the surrounding tissue, ﬂuorescence spectroscopy
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alone makes it difﬁcult to assess the absolute PpIX concen-
tration. It is thus uncertain whether PpIX levels induced by the
administration of 20 mg kg)1 b.w. ALA are sufﬁcient for a
successful PDT throughout the entire target volume.
Here, we investigate the absolute PpIX concentration within
human brain tissue samples acquired during FGR. A proce-
dure for the solubilization of tissue samples and the subsequent
quantiﬁcation of the PpIX concentration is employed for tissue
samples including GBM, GS, AA, AO, AOA, AG and
nonneoplastic tissue. The results are discussed with respect to
tumor grade and the presence of tissue heterogeneities, such as
necrotic regions.
MATERIALS AND METHODS
Patients and treatment procedure. Freshly prepared solution of ALA in
normal drinking water (1500 mg ALA per 50 mL water at a dosage of
20 mg kg)1 b.w., Gliolan; medac GmbH, Wedel, Germany) was
administered to the patients ca 3 h before induction of anesthesia.
Resection in white light and ﬂuorescence mode was performed
employing a neurosurgical microscope (OPMI Pentero; Carl Zeiss
Meditec, Jena, Germany) according to the institutional guidelines.
During FGR, tissue resectates were collected, ﬁxed in formalin,
embedded in parafﬁn, sectioned and hematoxylin and eosin (H&E)
stained for routine histopathological analysis. Diagnosis and tumor
cell density (TCD) are listed in Table 1. At least one of the resected
tissue pieces was excluded from the routine procedure, protected from
further light exposure and stored on ice until further processing. A
smaller part of this sample was ﬁxed in formalin, embedded in parafﬁn
and sectioned. Staining with H&E and MIB-1 for the Ki67 labeling
index was performed for sample-speciﬁc diagnosis and for cell
proliferation status, respectively. The remaining volume was employed
for PpIX extraction as described below. This procedure did not
interfere with the neuropathological workup for full and proper tissue
diagnosis. The study was approved by the ethical committee of the
University Clinic, Großhadern, Munich, and informed consent was
obtained from all patients.
Extraction procedure. The tissue was cut into smaller pieces
(<0.1 g) and weighed. Where heterogeneities were visible, such as
dark-appearing necrotic regions, effort was made to analyze these
separately. In adaptation to the protocol described earlier (25,26), each
sample was immersed in 1 mL Solvable (Perkin Elmer LAS, Groningen,
The Netherlands) and placed in a heated (45–50C) ultrasound
bath until the tissue was completely dissolved. Solvable is a product
designed to solubilize the tissue and contains a mixture of dodecyl-
dimethyl-aminoxide, secondary alcohol ethoxylate, sodium hydroxide
and water. From this solution, three aliquots of 10–80 lL each were
diluted in 1 mL Solvable and placed in the ultrasound bath for another
15 min. Care was taken to limit light exposure during the solubiliza-
tion process. Seven hundred microliters of this solution was ﬁlled into
a 2 mm optical pathlength quartz cuvette. Absorption spectra
(k = 350–750 nm, Lambda40; Perkin Elmer GmbH, U¨berlingen,
Germany) were obtained and if necessary further dilution with
Solvable was performed to ascertain an optical density below 0.1.
Fluorescence spectroscopy (kexc = 400 nm, kem = 450–780 nm, Flu-
oromax-2; Instruments S.A. Inc., NJ) was employed to quantify the
PpIX concentration, cPpIX. Each ﬂuorescence spectrum was analyzed
by ﬁrst subtracting a background ﬂuorescence spectrum, obtained
from pure Solvable. A Gaussian curve was ﬁt to the data points in the
wavelength intervals 500–600 and 750–780 nm, thus representing an
interpolation of the autoﬂuorescence from dissolved tissue. This
component was subtracted and the resulting ﬂuorescence intensity, in
counts per second (cps) per g tissue, at 634 nm was used to quantify the
PpIX concentration.
A calibration curve, relating the measured cps per g tissue to the
true PpIX concentration was obtained by dissolving brain tumor
tissue, obtained from a GBM where white-light resection had been
performed without ALA administration, in Solvable according to the
Table 1. Patients’ data, the resulting PpIX concentration (cPpIX) and the corresponding Ki67 labeling index.
Patient Age ⁄ sex
Diagnosis ⁄TCD
(routine H&E) Sample site m (g) cPpIX ± SD (lM) Ki67 (%)
1 64 ⁄M GBM ⁄middle–high Vital tumor 0.040 6.2 ± 0.2 –
2* 60 ⁄M GBM ⁄ high Vital tumor 0.049 3.8 ± 1.0 22
3* 25 ⁄F GBM ⁄ high Vital tumor 0.042 11.5 ± 6.8 32
4 54 ⁄F GBM ⁄ high Vital tumor 0.084 13.5 ± 10.7 40
5 45 ⁄M GBM ⁄middle Vital tumor 0.032 0.5 ± 0.2 18
6* 31 ⁄M GBM ⁄ high Inﬁltr tumor 0.027 2.1 ± 0.4 30
7* 64 ⁄F GBM ⁄ varying a) Inﬁltr tumor 0.013 1.6 ± 0.1 17
b) Nonneopl 0.087 0.0 ± 0.0 0
8 44 ⁄F GBM a) Vital tumor 0.006 1.3 ± 0.0 –
b) Inﬁltr tumor 0.013 0.0 ± 0.0 1
9* 69 ⁄M GBM a) Vital tumor 0.0234 1.9 ± 0.0 20
b) Necr 0.0912 0.3 ± 0.1 0
10 67 ⁄F GBM Necr 0.104 1.3 ± 1.3 0
11 59 ⁄F GBM Inﬁltr tumor 0.176 0.2 ± 0.1 6
12 48 ⁄M GBM ⁄ high Necr 0.022 0.0 ± 0.0 0
13* 69 ⁄F GBM ⁄ high Nonneopl 0.166 0.2 ± 0.2 0
14* 65 ⁄M GBM Nonneopl 0.018 0.0 ± 0.0 0
15 58 ⁄F GBM Nonneopl 0.013 0.1 ± 0.0 0
16 52 ⁄F GS ⁄ high Vital tumor 0.214 7.3 ± 3.0 21
17* 26 ⁄F GS Necr 0.040 0.3 ± 0.2 0
18 42 ⁄M AO ⁄ high Vital tumor 0.035 0.8 ± 0.1 23
19 45 ⁄M AOA ⁄middle a) Vital tumor 0.053 0.0 ± 0.0 10
b) Nonneopl 0.043 0.0 ± 0.0 0
20* 53 ⁄M AA ⁄middle Vital tumor 0.071 0.0 ± 0.0 9
21 38 ⁄M AA ⁄middle–high Vital tumor 0.064 0.1 ± 0.0 0
22 66 ⁄M AG ⁄middle Nonneopl 0.036 0.0 ± 0.0 0
AA = anaplastic astrocytoma grade III; AG = anaplastic ganglioglioma grade III; AO = anaplastic oligodendroglioma grade III; AOA =
anaplastic oligoastrocytoma grade III; GBM = glioblastoma multiforme grade IV; GS = gliosarcoma grade IV; nonneopl = nonneoplastic tissue;
necr = necrosis, TCD = tumor cell density. *Primary tumor.
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procedure described above. Known amounts of PpIX (Sigma Aldrich
GmbH, Steinheim, Germany) from a Solvable-based stock solution
with cPpIX = 10 lM were added and the ﬂuorescence intensity was
analyzed as described above.
The nonparametric Mann–Whitney U-test was employed for testing
statistical signiﬁcance at the P = 0.05 level. The correlation coefﬁcient
was calculated as
rx;y ¼ covðx; yÞrxry
where cov denotes the covariance and r the standard deviation.
RESULTS
Extraction procedure
Figure 1a shows the calibration curve relating ﬂuorescence
intensity, resulting from three independent measurements
and expressed in cps, at 634 nm to absolute PpIX concen-
tration. Figure 1b shows the PpIX ﬂuorescence intensity as a
function of the immersion time, postdilution, of GBM tissue
in Solvable. Although the ﬂuorescence intensity of PpIX in
Solvable decreases with time, less than 5% variations were
observed during the analysis procedure, i.e. within the ﬁrst
2 h. The minimum detection limit for tissue samples weigh-
ing 0.02 g was ca 0.1 lM. Typically, the resulting cPpIX varied
by less than 10% between aliquots from the same tissue
sample.
PpIX quantiﬁcation
The average, sample-speciﬁc PpIX concentrations are listed in
Table 1 and displayed in Fig. 2 as a bar plot. Each bar
represents a separate tissue sample as obtained during the
FGR procedure and numbers above the bars denote the
number of subvolumes processed per tissue sample, e.g. as
required to keep dissolved sample weight below 0.1 g or when
separately analyzing heterogeneous structures. Error bars,
indicating standard deviations, thus originate from spatial
differences in PpIX accumulation but also to a minor part
from variations between the three aliquots employed in the
dilution procedure. The results indicate large intra- and
interpatient variability of PpIX uptake. Particularly large is
the intratumor heterogeneity for patients 3, 4, 10 and 16. As
the extraction procedure requires relatively large tissue
samples, the resulting PpIX concentration represents an
average over a tissue volume possibly containing varying
Figure 1. (a) Fluorescence intensity (cps) at 634 nm versus PpIX
concentration resulting in an average R2 = 0.9974. Error bars denote
standard deviations resulting from three independent measurement
series. (b) Fluorescence intensity as a function of immersion time in
Solvable. Data have been normalized to the value at t = 0. Fluores-
cence data were acquired from a GBM with average cPpIX = 6.7 lM.
Figure 2. The absolute PpIX concentration for each patient. Primary tumors are indicated by *. Indicated are also the number of tissue samples
analyzed and the corresponding standard deviations.
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TCD and cell viability. For patients where two samples were
analyzed, e.g. patients 7, 8, 9 and 19, it is possible that no
single sample represented only the one or the other tissue
type, thus explaining the lower uptake in the malignant
samples for these patients. For vital grade III and IV tumors
a higher PpIX accumulation was observed for high TCD as
compared with samples presenting lower TCD, inﬁltrating
tumor cells or necrotic regions. From this study one cannot
conclude what is the cell-to-cell variation of PpIX uptake and
whether it is cancer cell speciﬁc. PpIX levels in nonneoplastic
samples were undetectable with the exception of patients 13
and 15. For these patients, the presence of PpIX might be due
to smaller regions with GBM tissue not present in the
subvolumes investigated by H&E staining. The correlation
coefﬁcient between cPpIX and the Ki67 labeling index was 0.78.
Water-soluble porphyrins, such as uro- and coproporphyrin,
were observed via ﬂuorescence between 610 and 620 nm for
patients 5, 9, 17 and 20. The presence of these ﬂuorescence
componentswasalsoassociatedwith relatively lowPpIXuptake.
The diagnosis-speciﬁc PpIX concentration is shown in
Fig. 3. The PpIX concentration was 5.8 ± 4.8 lM
(mean ± SD, range: 0–28.2 lM) for vital grade IV tumors,
i.e. GBM and GS with high TCD, 1.0 ± 1.0 lM (mean ± SD,
range: 0–2.5 lM) for inﬁltrating grade IV tumors,
0.5 ± 0.5 lM (mean ± SD, range: 0–2.3 lM) for grade IV
tumors with necrotic parts and 0.2 ± 0.4 lM (mean ± SD,
range: 0–0.9 lM) for grade III tumors, i.e. AA, AO, AOA and
AG. The median PpIX uptake was below the actual detection
limit for nonneoplastic tissue. Hence, the PpIX uptake seems
to correlate with tissue malignancy. The Mann–Whitney U-test
indicated signiﬁcant differences between vital grade IV tumors
and grade III tumors, necrotic parts of grade IV tumors as well
as nonneoplastic brain tissue. No statistically signiﬁcant
differences could be observed between primary and recurrent
GBM or GS.
DISCUSSION
ALA-induced PpIX has been successfully employed for FGR
of human malignant gliomas, resulting in improved treatment
outcome as compared with surgery performed under white
light alone (11). Furthermore, ALA-mediated brain-PDT is
currently being investigated and initial clinical trials have
shown promising results in terms of survival (13,17,18). Here,
we have investigated the absolute PpIX concentration in brain
tissues following oral ALA administration at 20 mg kg)1 b.w.
with the motivation to elucidate whether ALA-induced PpIX
levels are sufﬁcient for an effective PDT.
The Solvable-based solubilization process was easily imple-
mented and was characterized by low cost, good accuracy and
high reproducibility. Evidence of chemical bleaching could be
observed as the immersion time in Solvable was increased, in
agreement with a previous report (26). However, for the time
period relevant for the solubilization process the PpIX
ﬂuorescence displayed less than 5% variations. In agreement
with the results published for meso-tetra(hydroxyphenyl)chlo-
rin (mTHPC) quantiﬁcation in rat liver tissue (26), the use of
100% Solvable during the entire solubilization process and
proper subtraction of the autoﬂuorescence component were
necessary for obtaining sufﬁcient accuracy and reproducibility.
The light levels employed during FGR have been shown to
induce only moderate photobleaching (27) and hence we did
not consider any decrease in PpIX levels due to the FGR
procedure. The assumption of no pronounced photobleaching
was supported by the absence of photoproduct ﬂuorescence
around 670 nm both in dissolved tissue and within intact tissue
as measured via ﬁber-based ﬂuorescence spectroscopy (data
not shown).
The absolute PpIX concentration was found to range
between 0 and 28.2 lM in the human brain tissue samples
investigated. Large variations were observed within tumors as
well as with respect to individual patients and diagnoses. This
variability is expected due to the natural heterogeneity in
malignant tissue with neighboring vital, necrotic and inﬁltrat-
ing tumor parts. In this study, signiﬁcantly higher PpIX levels
were observed in vital grade IV tumors as compared with
grade III tumors. Moreover, within grade IV tumors, PpIX
levels varied signiﬁcantly between different tumor areas; the
highest PpIX concentrations were observed within vital tumor
parts, followed by inﬁltration zones adjacent to normal brain
tissue and necrotic areas. The PpIX ﬂuorescence has previ-
ously been observed to increase with tumor grade as well as
with TCD (27,28). In agreement with these publications, our
study also indicated lower average PpIX concentration within
inﬁltrating tumor tissue as compared with vital grade IV
tumors. However, the differences were not statistically signif-
icant as might be explained by the heterogeneity of the tissue.
Provided that PpIX uptake is tumor cell selective, the varying
TCD in inﬁltration zones makes the PpIX distribution very
patchy on a microscopic scale. The extraction procedure
allowed characterization of the PpIX concentration only on a
macroscopic scale and hence these cell-to-cell variations
remain unknown.
Undetectable or only very low PpIX levels were found in
nonneoplastic brain tissue, an observation in agreement with
previous ﬂuorescence spectroscopy studies (29). Others have
detected PpIX ﬂuorescence from outside tumor tissue for
recurrent malignant gliomas and metastatic brain tumors,
where also edema, inﬂammatory cells and inﬁltrating astro-
cytes could be observed (28). That study unfortunately did not
provide any information on the absolute PpIX concentration
Figure 3. The PpIX concentration as averaged for each diagnosis.
Error bars denote standard deviations and * indicates statistically
signiﬁcant differences in PpIX concentration at the P = 0.05 level.
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and hence it is difﬁcult to put these observations in relation to
the minimum detection limit of our extraction protocol. The
low but detectable PpIX levels for Patients 13 and 15, both
diagnosed as GBM on the routine histopathological analysis
but showing nonneoplastic tissue in the sample site, might
possibly be due to edema-induced leakage of PpIX from tumor
into surrounding tissue as previously proposed (28,30).
Furthermore, sampling error cannot be ruled out completely
due to the tissue acquisition and analysis procedure.
Our results also show that the low PpIX ﬂuorescence
typically observed in vivo from dark-appearing, necrotic tissue
is to a great extent due to true concentration variations. This
observation is in agreement with previous reports, where, e.g.
no PpIX ﬂuorescence could be observed from necrotic tumor
regions during FGR of GBM (29). A correlation between
PpIX ﬂuorescence and tissue proliferation status, as indicated
by the MIB-1 labeling index, has been reported (24), indicating
the importance of cell proliferation activity for ALA-to-PpIX
conversion. This observation was conﬁrmed in our study by
the signiﬁcant correlation between the absolute PpIX concen-
tration and the Ki67 labeling index. Interestingly, the presence
of ﬂuorescence peaks between 610 and 620 nm was associated
with low PpIX uptake in our study. Reduced mitochondrial
viability has been reported to lead to the induction of water-
soluble porphyrins in vivo following ALA administration (31),
possibly indicating reduced cell viability within the tissue
samples of patients 5, 9, 17 and 20.
Taken together, investigations of the PpIX uptake in
relation to local TCD and cell viability on the microscopic
scale are warranted. Only by such studies the possibility of
sensitizing individual tumor cells that inﬁltrate normal, sur-
rounding tissue as well as the risk of unintentionally sensitizing
normal, surrounding brain tissue can be judged.
Reports on absolute PpIX concentration in relation to the
resulting PDT effect in human tissues are rare. For various
human skin malignancies, topical application of ALA has been
reported to result in cPpIX = 1–2 lM (32). As that study
employed the same ALA administration procedure as used
conventionally (4–6 h application times of 20% ALA in
ointment) for ALA-mediated skin-PDT (33), PpIX levels in
this range seem sufﬁcient for PDT of superﬁcial skin malig-
nancies when irradiated at 75 J cm)2. Similarly, oral ALA
administration (30–50 mg kg)1 b.w.) has been reported to
induce cPpIX = 2–9 lM in human Barrett’s esophagus (34).
The subsequent irradiation with 100–200 J cm)2 at 635 nm has
been employed for efﬁcient PDT (35). Studies in various
animal tumor models contain more comparative data on
absolute PpIX levels and subsequent PDT efﬁcacy. For
example, in the 9L gliosarcoma rat brain tumor model,
repetitive ALA administration was shown to induce PpIX
levels in the 2–5 lM range, a photosensitizer concentration that
also led to pronounced tissue damage following interstitial
irradiation with 50 J (36). PpIX concentrations between 10
and 20 lM have been observed in rat stomach (37), where PDT
at 50 J was also shown to induce signiﬁcant PDT damage (38).
PpIX levels in murine and rat tumor models in the range of
1–10 lM are generally sufﬁcient for inducing phototoxic effects
(see e.g. 39–41).
The PpIX levels observed within vital grade IV malignancies
in this study are thus in the range previously shown sufﬁcient
for PDT-induced tissue damage. Of course, one needs to be
careful in extrapolating the results from human skin and
Barrett’s esophagus and from various animal tumor models to
human malignant gliomas. For an effective PDT, it is also
crucial to ascertain a sufﬁcient light dose and oxygen supply.
In this respect, hypoxic regions, areas of spontaneous necrosis
and tumor inﬁltration zones might require special consider-
ation. The varying PpIX levels observed between patients and
within tumor samples indicate that PDT dosimetry based
solely on the administered light and drug doses is insufﬁcient
for predicting and ⁄ or controlling the therapeutic outcome.
Although the bulk average PpIX concentration of inﬁltrating
tumor tissue seems to be insufﬁcient for PDT, it remains to be
elucidated whether the uptake in individual inﬁltrating tumor
cells is enough to selectively target the malignant cells within
the inﬁltration zones.
In summary, large intertumoral variations of PpIX uptake
following oral ALA administration were evident as well as
large differences between solid, necrotic and inﬁltrating tumor
parts. For vital grade IV tumors, the PpIX concentrations as
averaged over the bulk of the tissue sample were in the range
previously shown sufﬁcient for PDT-induced tissue damage
following irradiation. Grade III, nonneoplastic samples as well
as grade IV tumors with mainly necrotic parts exhibited
signiﬁcantly lower PpIX uptake. It remains to be elucidated
whether PpIX levels in lower-grade brain tumors, inﬁltrating
tumor tissue and higher-grade tumors with signiﬁcant necrotic
volumes are sufﬁcient for an effective PDT.
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Background and Objective: Interstitial photodynamic
therapy (iPDT) of non-resectable recurrent glioblastoma
using 5-aminolevulinic acid (ALA)-induced protoporphy-
rin IX (PpIX) has shown a promising outcome. It
remained unclear, however, to what extent inter- and
intra-tumoural differences of PpIX concentrations inﬂu-
ence the efﬁcacy of iPDT. In the current pilot study,
we analysed PpIX concentrations quantitatively and
assessed PpIX induced ﬂuorescence and photobleaching
intraoperatively.
Materials and Methods: Five patients harbouring non-
resectable glioblastomas were included. ALA (20 or
30 mg/kg body weight) was given 5–8 hours before treat-
ment. Stereotactic biopsies were taken throughout the
tumour volume for both histological analysis and determi-
nation of PpIX concentrations, which were measured by
chemical extraction. Cylindrical light diffusors were ste-
reotactically implanted. Prior to and after irradiation,
ﬂuorescence measurements were performed. Outcome
measurement was based on clinical and neuro-radiologi-
cal follow up.
Results: In three patients, a strong PpIX ﬂuorescence
was seen before treatment, which was completely photo-
bleached after iPDT. High concentrations of PpIX could
be detected in viable tumour parts of these patients
(mean PpIX uptake per tumour: 1.4–3.0 mM). In the other
two patients, however, no or only low PpIX uptake (0–
0.6 mM) could be detected. The patients with strong PpIX
uptake showed treatment response and long-term clinical
stabilisation (no progression in 29, 30 and 36 months),
early treatment failure was seen in the remaining two
patients (death after 3 and 9 months).
Conclusions: Intra-tumoural PpIX concentrations exhib-
ited pronounced inter- and intra-tumoural variations in
glioblastoma, which are directly linked to variable
degrees of ﬂuorescence intensity. High intra-tumoural
PpIX concentrations with strong ﬂuorescence intensity
and complete photobleaching after iPDT seem to be asso-
ciated with favourable outcome. Real-time monitoring of
PpIX ﬂuorescence intensity and photobleaching turned
out to be feasible and safe and might be employed for
early treatment prognosis of iPDT. Lasers Surg. Med.
 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most malignant
human brain tumour. Modern standard treatment, which
includes surgery in combination with external beam radi-
ation plus concomitant and adjuvant temozolomide che-
motherapy, has signiﬁcantly improved survival time
(median: 15 months). Moreover, silencing of the DNA re-
pair enzyme O(6)-methylguanine-DNA methyltransferase
(MGMT) has been shown to be associated with an addi-
tional approximately twofold median survival advantage
after radiochemotherapy. Overall, however, the prognosis
for patients with GBM is still dismal. Even though glio-
blastomas are tumours, which widely inﬁltrate the sur-
rounding brain parenchyma, localised treatment
strategies such as open tumour resection have been
shown to be beneﬁcial for selected patients [1]. Given the
fact that not all patients are suitable for open tumour re-
section because of an unfavourable (risky) tumour loca-
tion and/or signiﬁcant co-morbidity, alternative
treatments, such as stereotactic radiotherapy or intersti-
tial laser-thermotherapy might be employed. Stereotactic
iPDT has shown initial promising results [2], tempting us
to further develop and improve this alternative method
for selected cases.
PDT relies on the light-induced activation of a photo-
sensitiser and the subsequent formation of different reac-
tive radicals and oxygen species, which in turn cause
cellular damage. Since its clinical introduction in 1980 for
the treatment of human brain malignancies, hematopor-
phyrin derivative (HpD) and its puriﬁed versions photo-
frin and photosan, also referred to as ﬁrst generation
photosensitisers, have been the most commonly employed
photosensitisers for brain-PDT [3–5]. Whereas the thera-
peutic irradiation is most often applied within the surgi-
cal cavity following resection [5,6], interstitial PDT
(iPDT) relies on thin optical ﬁbres being inserted into the
tumour mass [3,5,7–9].
In an effort to circumvent the risks associated with the
use of the ﬁrst generation photosensitisers, studies
employing 5-aminolevulinic acid (ALA) for iPDT have
been carried out at the University Hospital of Munich.
ALA is a pre-cursor that is converted into the actual pho-
tosensitiser, protoporphyrin IX (PpIX), as a part of the en-
dogenous heme-synthesis [10]. Oral ALA administration
leads to high tumour-selective PpIX accumulation [11]
and shorter time periods of general photosensitisation as
compared to HpD and photofrin. Generally, the selectivity
is explained by a decreased ferrochelatase activity within
cancer cells, thus limiting the conversion efﬁciency of
PpIX to heme [12] and an increased activity of the rate
limiting enzyme porphobilinogen deaminase (PBGD) in
tumour tissue [13]. The limited ability of ALA to pene-
trate the intact blood brain barrier (BBB) also contributes
to the tumour-selective PpIX uptake [14]. In a feasibility
study, 10 patients suffering from recurrent GBM were
treated by means of ALA-mediated iPDT [2]. In that
study, we aimed at administering a light dose exceeding
the pre-determined threshold dose to the entire target vol-
ume without considering variations in light distribution,
initial PpIX concentration and oxygen availability during
iPDT. Such a dosimetry model might be justiﬁable, if the
photosensitiser displays good tumour selectivity as dis-
cussed in Ref. 15 and if photosensitiser and oxygen con-
centrations pose no limitation. The patients treated with
iPDT in that study had a median survival of 15 months.
Four patients lived longer than 24 months, two of them
longer than 48 months [2] and one of them [16] was still
alive at the last follow-up at 7 years. However, a third of
the patients did suffer early progression. Partly, this may
be attributed to the fact that the current dosimetry mod-
els of iPDT rely only on the delivered light and photosen-
sitiser, but patient-speciﬁc, spatially- and time-dependent
variations of light, photosensitiser and oxygen distribu-
tions are not considered [15]. Further reasons for the
large heterogeneity in treatment response, including the
occurrence of long-term survivors as well as early treat-
ment failures, might be the variability of light distribu-
tion, differences in photosensitiser accumulation [8,17]
and different synergism between iPDT and the immune
response [18]. Further, iPDT could induce changes in tis-
sue oxygenation and blood ﬂow [19].
Hence, increasing effort has been undertaken to imple-
ment real-time treatment monitoring during iPDT. In the
explicit dosimetry model one aims at separately monitor-
ing the light, photosensitiser and tissue oxygenation lev-
els [20–22]. In contrast to this, the implicit dosimetry
model aims at tracking one single parameter, such as the
photosensitiser photobleaching kinetics, that implicitly
contains information on the total PDT dose [23]. This
model relies on the assumption that PDT-induced singlet
oxygen causes tissue damage as well as photodegradation
of the photosensitiser. The usefulness of an implicit do-
simetry model has been conﬁrmed in pre-clinical models
[24,25] as well as for human skin-PDT [26,27] where a
rapid photobleaching has been shown to correlate with
improved treatment outcome. Speculatively, the PpIX-
speciﬁc photobleaching kinetics might be employed for
early treatment prognosis and to assure the application of
a sufﬁcient light dose in order to improve treatment efﬁ-
cacy [28].
With the aim to investigate possible reasons for the ob-
served variability in treatment response to brain-iPDT,
we analysed patient-speciﬁc photosensitiser accumulation
and photobleaching. Here, we present a clinical procedure
for iPDT with parallel, minimally invasive spectroscopic
monitoring of both, PpIX ﬂuorescence intensity and pho-
tobleaching efﬁciency. The PpIX-speciﬁc ﬂuorescence
measured in vivo is compared to the absolute PpIX con-
centration as quantiﬁed in tissue biopsies obtained prior
to iPDT. The patient-speciﬁc PpIX uptake and photo-
bleaching are put in relation to the patient-speciﬁc histo-
pathology and to the iPDT-induced changes on early
magnetic resonance imaging (MRI) data. We further
linked these ﬁndings to the clinical outcome of the investi-
gated patients. Finally, we speculate on the use of in vivo,
real-time spectroscopic monitoring as a tool for early
treatment prognosis along the lines of an implicit dosime-
try model.
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PATIENTS ANDMETHODS
Patient Selection
Adult patients with a circumscribed glioblastoma with
a maximum diameter of 3 cm as deﬁned by gadolinium
enhanced T1 weighted MRI and a Karnofsky Performance
Status (KPS) of at least 70 were considered eligible for the
study. A conﬁrmatory stereotactic biopsy was performed
for all patients as detailed below. All patients gave writ-
ten informed consent. The prospective study protocol
allowing spectroscopic and molecular-genetic analyses of
tissue samples, which were collected by stereotactic
biopsy before iPDT, was reviewed and approved by the
institutional review board of the Ludwig-Maximilians-
University, Munich, Germany (AZ 216/14).
Stereotactic Treatment Planning
Treatment planning was based on multi-modal imaging
data. Image fusion of the stereotactically localised compu-
terised tomography (CT; contrast enhanced scans, 2 mm
slices), with additional MRIincluding gadolinium enhanced
T1-(1 mm slices) and T2-weighted scans (2 mm slices), and
O-(2-[18F]ﬂuoroethyl)-1-tyrosine (18FET)-Positron Emission
Tomography (PET) scans were acquired for optimal visuali-
sation of the tumour and to deﬁne the treatment volume
(Image Fusion Software, BrainLAB AG, Heimstetten,
Germany). Irradiation planning was performed with the
@target 1.19 software (BrainLAB AG). The positions of the
therapeutic light sources were determined by manually
optimising overlap between tumour and treatment volumes
while at the same time guaranteeing a minimum source
separation of 8 mm. Here, treatment volume was deﬁned
as the iso-dose curve at 1,870 J/cm2 (assuming absorption,
ma, and reduced scattering, m
0
s, coefﬁcients of 0.2 and
20 cm1, respectively). Further details on the treatment
planning procedure can be found in [2].
Molecular Stereotactic Biopsy Technique
The intended drug dose was 30 mg/kg body weight ALA
(medac GmbH, Wedel, Germany) dissolved in 100 ml
water and applied orally. The dose used for ﬂuorescence
guided open resection of glioblastomas is 20 mg/kg which
has been shown to be well tolerated by the patients [11].
Other groups, however, have used higher ALA doses (in
the range of 40–60 mg/kg) for PDT treatments of tumours
of the urinary bladder [29] and oesophagus [30,31]. In
the current study we decided to use a dose in between
these extremes. For safety reasons this dose was further
reduced to 20 mg/kg for Patent 1 as he had a small
tumour with little necrosis, see further Table 2. All
patients were treated under general anaesthesia. Intrao-
peratively, the oxygen saturation was set to 100% in order
to prevent a possible lack of cellular oxygen due to oxygen
consumption during the treatment. It has been shown
that oxygen ventilation can signiﬁcantly increase cerebral
oxygen tension by approx. 60% in an animal model [32].
Glioblastomas exhibit signiﬁcantly less oxygen tension
than normal human brain [33]. According to these data it
can be expected that ventilation with 100% O2 also
increases the local pO2 within the GBM tissues. However,
this assumption needs further elucidation. Immediately
prior to iPDT a molecular serial stereotactic biopsy was
performed as described previously [34]. In brief, co-regis-
tration of CT, MRI and FET–PET imaging (as described
above) served for 3D visualisation of the tumour and
simulation of the optimal trajectory. Serial biopsies were
taken along this trajectory in 1 mm steps. Using micro-
forceps, the maximum amount of tissue per biopsy speci-
men was 1 mm3. The tissue sampling procedure was
guided by intra-operative smear preparations, routinely
performed by the attending neuropathologist, and
guaranteed sampling of both the solid and necrotic
tumour volumes. Tissue probes were employed for histo-
pathological examination, including the tumour cell
density (TCD), the tumour proliferation status (via the
Ki67 labelling index), for molecular-genetic analyses
such as the determination of O(6)-methylguanine-DNA
methyltransferase (MGMT) promoter methylation status
(Table 1) and for PpIX extraction and quantiﬁcation as
described below.
TABLE 1. Patient Data
Patient Age/sex Diagnosis Treatment history TCD/Ki67(%)/MGMT
Tumour volume
(cm3)
1 42/M prim. GBM — Medium/10/negative 1.5
2 48/M rec. GBM res, RCT, temozolomide Low-medium/5/positive 10.0
3 50/M rec. GBM res, temozolomide, RCT, temozolomide High/1/positive 1.7
4 76/M rec. GBM RCT Medium/1/partially positive 7.0
5 50/F rec. GBM res þ RT, res þ RIT, temozolomide,
seed implantation, temozolomide, seed
implantation, Avastin-PC-chemotherapy
Medium/50/positive 9.4
Tumour volume was determined based on the fused MR (T1-weighted gadolinium-enhanced and T2-weighted) and CT images
prePDT.
MGMT, methyl guanine methyl transferase; RCT, radiotherapy plus concomitant and adjuvant temozolomide; res, resection;
RIT, radio-immuno therapy; RT, radiotherapy; TCD, tumour cell density.
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Stereotactic Interstitial Photodynamic Therapy
(iPDT)
The ﬁbres for therapeutic light delivery consisted of
four to six 600-mm diameter cylindrical diffusers (Fig. 1;
Light Guide Optics, Rheinbach, Germany) with 20 or
30 mm length, see further Table 2. Diffusor length was at
least equal to the tumour extension along the insertion
trajectory. These ﬁbres were inserted via a stereotactic
approach, employing a modiﬁed Riechert-Mundinger ste-
reotactic frame, and ﬁbre positions were controlled via X-
ray markers on the cylinders and an orthogonal C-arm. A
multi-port laser system (4 ports, 635 nm, 2 W maximum
output power per port, Ceralas PDT Diode Laser, biolitec
AG, Jena, Germany) was used as the light source. For
patients 2 and 5, the addition of a custom-made beam
splitter unit allowed the use of six and ﬁve source ﬁbres,
respectively. Therapeutic irradiation was performed with
a constant power of 150 or 200 mW/cm to a total delivered
light dose of 720 J/cm per ﬁbre. Due to different expendi-
ture of time for stereotactic treatment planning and
ﬁbre placement, the irradiation occurred 5–8 hours after
ALA administration. The PDT was supplemented with
in situ spectroscopic measurements pre- and post-PDT as
detailed below.
Extraction Procedure
The biopsies collected for PpIX quantiﬁcation were
weighed, immersed in 1–2 ml solvable (Perkin Elmer
LAS, Groningen, The Netherlands) and placed in a heated
(45–508) ultrasound bath until the tissue was completely
dissolved. Care was taken to limit light exposure during
the solubilisation process. Seven hundred microlitre of
this solution were ﬁlled into a 2-mm optical path length
quartz cuvette. Absorption spectra (l ¼ 350–750 nm,
Lambda40, Perkin Elmer GmbH, U¨berlingen, Germany)
were obtained and if necessary further dilution with
solvable was performed to ascertain an optical density
below 0.1. Fluorescence spectra were obtained from
pure solvable and from dissolved tissue (lexc ¼ 400 nm,
lem ¼ 450–780 nm, Fluoromax-2, Instruments S.A., Inc.,
Edison, NJ). Fluorescence from solvable and the auto-
ﬂuorescence of dissolved tissue was subtracted and the
resulting ﬂuorescence intensity, in counts per second
(cps)/g tissue, at 632 nm was used to quantify the PpIX
concentration, cPpIX. A calibration curve was obtained by
adding known amounts of PpIX to dissolved GBM brain
tissue obtained from a patient where white-light resection
had been performed without ALA administration. The
procedure is detailed in Ref. 8.
In Vivo Spectroscopy
In situ spectroscopic measurements of the light trans-
mission between therapeutic ﬁbres were performed prior
to and post-iPDT via the setup illustrated in Figure 1.
Sequentially, each ﬁbre was set to emit 200 mW/cm at
635 nm and each of the remaining ﬁbres was employed to
detect the light transmission between 630 and 800 nm.
An optical switch (MPM-2000, Mikropack, Ostﬁldern,
Germany) controlled, which ﬁbre was used for detection.
The detection unit consisted of a long pass ﬁlter
(RG645, Schott Glas, Mainz, Germany) and a miniature
TABLE 2. Treatment Details
Patient
Number biopsies
PpIX/H&E
ALA
(mg/kg b.w)
DLI
(hours)
Number
fibres
Light dose
(J)
Source strength
(mW/cm)
Source length
(cm)
1 10/11 20 8 4 5,760 200 2
2 6/6 30 5 6 12,960 150 2
3 3/5 30 5&6y 4 5,760 200 2
4 5/3 30 5 4 5,760 200 3
5 5/6 30 6 5 10,800 200 3
DLI, drug-light interval.
Biopsies were obtained 1 day prior to PDT.
yIrradiation was performed in two consecutive sessions with two ﬁbres active at a time.
Fig. 1. Principal setup for iPDT of brain tumours with real-
time spectroscopic monitoring. The switching unit controlled
which ﬁbre was employed as a detector ﬁbre. Inset is a photo-
graph of the clinical setting during iPDT where optical ﬁbres,
metal catheters and the ﬁxation device onto the stereotactic
frame can be seen.
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spectrometer (S2000 alternatively USB2000þ, Mikro-
pack). By properly choosing cut-on wavelength and thick-
ness of the longpass ﬁlter, simultaneous detection of the
light transmission at 635 nm and ﬂuorescence between
670 and 800 nm was possible. Hence, minimally invasive
in situ measurements could be performed without the
need for additional ﬁbre probes. The 635-nm light trans-
mission was assessed as the maximum signal between
630 and 640 nm. In order to avoid absolute ﬂuorescence
measurements, the PpIX ﬂuorescence F at 700 nm was
determined relative to the autoﬂuorescence background
according to Equation (1)
F ¼ I700nm  kI750nm
kI750nm
(1)
I700 nm is the signal at 700 nm, and the term kI750 nm
is an estimate of the autoﬂuorescence contribution
at 700 nm, which has to be subtracted from I700 nm in
order to assess the PpIX-speciﬁc ﬂuorescence compo-
nent. At 750 nm no PpIX ﬂuorescence is expected. The
k-value was determined by the analysis of spectra exhib-
iting exclusively autoﬂuorescence. For this purpose,
only those post-iPDT spectra were considered, which
had no evident PpIX-component even before iPDT.
From these pure autoﬂuorescence spectra, a mean ratio
of I700 nm/I750 nm ¼ 2 was determined and accordingly,
k was set equal to 2. In order to reduce the signal-to-
noise ratio, only ﬁbre pairs with source-detector separa-
tions (cylinder centre-to-centre distances) smaller than
15 mm were included in the data analysis. The mini-
mum distance was 8 mm.
Patient Evaluation After iPDT
All patients received dexamethasone in the ﬁrst 3 days
after the PDT. The ﬁrst post-operative MRI investigation
(gadolinium enhanced T1 weighted and T2 weighted
scans) was done at day 1 after surgery for assessment of
early treatment effects. The PDT effect was judged
based on the changes in MRI contrast agent uptake as
visually observed (Faber and Kreth). Further clinical and
neuroradiological follow-up was performed 1 month post-
operatively and thereafter at 3-month intervals at the
outpatient clinic.
RESULTS
The real-time PpIX ﬂuorescence monitoring during ste-
reotactically guided iPDT is feasible. It was intuitively in-
tegrated into the serial stereotactic biopsy approach.
Prior to the placement of light application ﬁbres for iPDT,
8–15 tissue samples were taken along one of the planned
treatment trajectories. Three to eight samples were used
for histopathological evaluation and molecular genetic
analysis, another 3–10 samples were collected to study
PpIX concentration. The diagnosis of glioblastoma was
conﬁrmed for all patients (Table 1).
The PpIX concentration measurements performed on
tissue biopsies and the intra-operative measurements of
ﬂuorescence intensities were analysed (Fig. 2). All
patients that showed high pre-irradiation PpIX ﬂuores-
cence (patients 1, 3 and 4), also showed a high PpIX con-
centration in the extracted tissue, at least in parts of the
tumour. The mean values of the PpIX concentrations
measured along the biopsy trajectories ranged from 1.4 to
3.0 mM for these patients (Fig. 2, columns 1 and 2). The
strongest PpIX ﬂuorescence intensity was found for pa-
tient 1, corresponding well with the PpIX extraction val-
ues, which were also among the highest of all patients.
Little PpIX-ﬂuorescence was found for patient 2, although
one tissue sample showed a high PpIX concentration.
This tumour was characterised by extensive necrosis.
Some samples taken adjacent to biopsy proven vital tu-
mour showed no PpIX. Patient 5 showed even less PpIX
ﬂuorescence. In this case, none of the extraction measure-
ments showed PpIX either. The analyses of spectral meas-
urements performed pre- and post-iPDT for patients 1, 3
and 4 showed high pre-irradiation PpIX ﬂuorescence and
very low post-irradiation PpIX-ﬂuorescence, indicative of
substantial photobleaching. For patient 2, a photobleach-
ing of the low average PpIX ﬂuorescence could not be
detected.
Furthermore, we compared the pre- and post-operative
contrast enhanced MRI images at representative posi-
tions of the tumours (Fig. 2, columns 3 and 4). The largest
differences in contrast uptake between pre- and post-oper-
ative imaging were observed for patients 1, 3 and 4, the
ones with the highest PpIX-signals. Patient 2 showed re-
duced contrast uptake only in parts of the tumour, for pa-
tient 5, contrast uptake was still visible in the post-
operative MRI.
Figure 3 shows examples of the ﬂuorescence spectra
measured with irradiation ﬁbres. A distinct PpIX ﬂuores-
cence peak around 700 nm can be seen in the pre-PDT
data for patient 1 and this characteristic ﬂuorescence was
photobleached during therapy. The spectrum from patient
2, on the other hand, displayed unspeciﬁc ﬂuorescence be-
tween 650 and 750 nm that was not characteristic of PpIX
but was also partly photobleached during PDT.
Intra-operatively determined PpIX concentration and
ﬂuorescence levels were correlated with clinical outcome
data and neuro-radiological follow up (Table 3). The re-
duction of contrast uptake observed post-operatively in
MRI analyses of patients 1, 3 and 4 was associated with a
favourable clinical outcome (responders), no progression
was observed for 29–36 months. In contrast, patients 2
and 5 with no intra-operatively detectable PpIX concen-
tration and ﬂuorescence showed no change in MRI con-
trast agent uptake and incurred clinical progress at 3 and
9 months, respectively (non-responders). Beyond these
ﬁndings, there was no clear evidence for a correlation be-
tween TCD, proliferation index or MGMT-status with the
clinical outcome (Tables 1 and 3).
DISCUSSION
iPDT is being investigated as a treatment option for
brain malignancies. Oral administration of ALA and
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Fig. 2. The curves in the 1st column show the absolute PpIX concentrations determined by
chemical extraction along the biopsy trajectories prior to PDT for all patients. The tumour
depth 0 mm corresponds with the distal tumour point along the trajectory. Areas of vital
tumour (T), necrosis (N), cortex (X) and inﬁltrating tumour (I) as determined from the H&E
stained biopsies (ﬁlled circles) and smear preparations (triangles) are also indicated. The
2nd column shows the mean ﬂuorescence signals F relative to the autoﬂuorescence mea-
sured between irradiation ﬁbres before and after each treatment session. Error bars denote
standard deviations resulting from averaging over all source and detector ﬁbre pairs with
distances <15 mm. The 3rd and 4th column show NMR images pre- and post-PDT. The
cross indicates the centre of the irradiated volume. The letters A, B and C in the 1st and 3rd
column for the 1st patient exemplarily mark corresponding positions.
subsequent irradiation at 635 nm has been shown to re-
sult in median survival of 15 months [2]. The clinical pro-
cedures employed by our group and other groups [2,15]
have so far involved only standardised light and ALA
doses. The observation of some intriguing long-term sur-
vivors leads to the speculation that some individuals
might present conditions that are particularly beneﬁcial
for PDT. Such conditions might include high PpIX uptake,
absence of hypoxic and necrotic tumour regions, as well as
good oxygen supply. In the current pilot study the feasibil-
ity and safety of iPDT was tested and the relation of PpIX
build-up and photobleaching to outcome measurement
was investigated.
The absolute PpIX concentrations observed were in the
range 0–4.2 mM for the ﬁve patients included in this re-
port. As reviewed in Ref. 8, the induction of efﬁcient pho-
todynamic effects in human and animal tissues is possible
with PpIX levels in the range of 1–10 mM. The three res-
ponders among the ﬁve patients indeed showed an aver-
age PpIX concentration in this range. Furthermore, the
observed range, and uptake, are in agreement with previ-
ously observed photosensitiser levels within brain tissue
samples acquired during ALA-mediated ﬂuorescence-
guided resection (FGR) [8,17,35]. This variability is
expected, due to the heterogeneous composition of the tu-
mour volume, consisting of neighbouring vital, hypoxic
and necrotic parts: Viable tumour tissue was character-
ised by the highest PpIX concentrations and ﬂuorescence
as shown in patients 1, 3 and 4. On the other hand,
tumours with extended central necrosis surrounded by
extremely thin layers of viable tumour tissue were char-
acterised by lower mean PpIX uptake, see for example in
patient 2. In patient 5 exhibiting no PpIX uptake and ﬂuo-
rescence, an exceptionally undifferentiated histopatholog-
ical phenotype was found; This patient had previously
been subjected to extensive multi-modal treatment. Al-
though one might expect an even increased PpIX-accumu-
lation capacity in highly undifferentiated and strongly
proliferating (Ki67 was 50%, Table 1) tumours, our
results indicate that extensive dedifferentiation of tumour
cells after previously performing multi-modal treatment
might hamper PpIX biosynthesis.
The applied dosimetry feedback model of this study
includes real-time monitoring of the PpIX ﬂuorescence in-
tensity and photobleaching. Such a model can be useful
for both the optimal adjustment of irradiation parameters
to achieve complete photobleaching of the treatment vol-
ume without employing unnecessarily long treatment
times and early prognostic evaluation [36]. The chosen ap-
proach is in accordance with the implicit dosimetry model
as proposed by Wilson et al. [23], who have assumed that
the same process(es) induce(s) both tissue damage and
photosensitiser consumption, thereby avoiding the need
to separately monitor light ﬂuence rate, photosensitiser
concentration and tissue oxygenation. The implicit dosim-
etry model holds the advantage that it is relatively
uncomplicated, technically easy and cheap. Our measure-
ment conﬁguration utilised the same ﬁbres and light
Fig. 3. Measured spectra, normalised at 650 nm showing
transmission signal at 635 nm suppressed by a longpass ﬁlter
and PpIX ﬂuorescence centred around 700 nm with auto-
ﬂuorescence background, pre- and post-PDT for patients 1
and 2. Source-detector separation was 10 and 11 mm for
patients 1 and 2, respectively.
TABLE 3. PpIX Concentrations in Biopsies, MRI Data and Follow-Up
Patient cPpIX (mM) MR imaging changes Follow-up status
1 1.4  1.4 (0–3.8) sign. regr. No progr. 36 months
2 0.6  1.2 (0–2.9) No change Progr., deceased after 3 months
3 3.0  1.8 (0.9–4.2) sign. regr. No progr. 30 months
4 1.8  0.8 (0.9–2.8) sign. regr. No progr. 29 months
5 0  0 No change Progr., deceased after 9 months
Average  standard deviation (range) of PpIX concentrations in biopsies (cPpIX), MRI data 1 day post-PDT and the patient
status at time of writing.
sign. regr., signiﬁcant regression; progr., progression.
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source as employed for therapeutic light delivery for
in vivo PpIX ﬂuorescence monitoring, thereby avoiding
the use of additional measurement ﬁbres.
In our opinion, essential requirements for a potentially
successful iPDT are, the proof of a sufﬁciently high PpIX-
concentration in vital malignant tissue in combination
with the application of a sufﬁciently high light ﬂuence to
all critical parts of the tumour. If the initial PpIX concen-
tration is too low, photobleaching will destroy the photo-
sensitiser before a lethal amount of intra-cellular reactive
oxygen species could be produced [15]. The low PpIX-accu-
mulation outside the tumour helps to avoid normal brain
injury [15]. In other words, there are relatively few safety
concerns regarding the application of high light doses. In
contrast any increase of the drug dose should be per-
formed extremely cautiously. In order to avoid thermally
induced side effects of iPDT in case of reduced inter-ﬁbre
distances, additional temperature measurements are
indicated.
The varying PpIX levels observed in this study indicate
that an iPDT dosimetry based solely on the administered
light and drug doses is insufﬁcient for predicting and/or
controlling the therapeutic outcome. The standardised ir-
radiation time of 3,600 seconds employed in our clinical
work is based on patient-averaged values for target tissue
optical properties and photobleaching kinetics [2,15,37].
Numerous groups are investigating different approaches
towards real-time treatment supervision relying on the
different, patient-individualised PDT dosimetry models,
for example for prostate-PDT [20–22] and PDT in intra-
peritoneal tissues [38]. Recently, Yang et al. [39] reported
on a setup and initial data employing combined ﬂuores-
cence imaging and non-contact point spectroscopy
during intraoperative, photofrin-mediated brain-PDT.
The authors speculate on the use of the system for indi-
vidualised PDT by identifying and targeting ﬂuorescent
tissue remaining post-FGR and/or to employ photobleach-
ing kinetics along the concept of an implicit dosimetry
model [23]. The true potential of treatment supervision
and feedback to individualise therapy is, however, still
relatively unexploited for brain-PDT. However, even with
establishing individualised treatment protocols, hypoxic
regions and areas of spontaneous necrosis probably need
special consideration due to their lower PpIX uptake [8],
limited light penetration [40] as well as poor oxygen
availability. A complete phototoxic eradication of all
tumour cells may thus be improbable. To obtain long term
survival one may have to rely on secondary effects, such
as shut down of tumour vasculature or induction of an
efﬁcient immune response. A shut down of tumour vascu-
lature might be caused by the development of a local ede-
ma within a around the treatment volume. Initial
research on ALA-PDT induced immune responses has al-
ready indicated, for example an increased expression of
heat shock proteins [41,42]. Similar responses, especially
a direct phototoxic action on the tumour vasculature
might also be initiated by other photosensitisers, such as
temoporﬁn, photofrin, or Tookad soluble, which are in
clinical use or clinical studies. However, in the current
study 5-ALA was preferred because of its high tumour
selectivity.
As a result of the ﬁrst pre- and post-iPDT intra-opera-
tive ﬂuorescence measurements, we observed an associa-
tion between initial PpIX concentration, ﬂuorescence
levels, photobleaching and clinical outcome data: patients
with high intra-operative PpIX intensity, high ﬂuores-
cence levels and pronounced photobleaching experienced
remarkably reduced MRI contrast agent uptake after
iPDT and favourable outcome with long term survival. As
there were no cases with high initial PpIX intensity and
no photobleaching after irradiation in the series, we could
not elucidate, whether pronounced photobleaching corre-
lates with treatment response and favourable outcome.
The absence of photobleaching, however, might indicate
insufﬁcient irradiation as a consequence of high tissue ab-
sorption or large interﬁbre distances. Patients with both
no or little intra-operatively detectable PpIX concentra-
tion and low ﬂuorescence levels before iPDT experienced
early progress. Hence, one might consider applying PpIX
ﬂuorescence measurements as early as the stereotactic bi-
opsy procedure, to select patients suitable for iPDT
[43,44]. In this session, PpIX concentration should be
measured quantitatively, either by applying quantitative
ﬂuorescence spectroscopy as suggested by several groups
(see for example [45–48]) or by chemical extraction from
biopsies.
CONCLUSION
Treatment monitoring by detecting PpIX ﬂuorescence
during iPDT of glioblastoma is feasible and safe. Intra-
tumoural PpIX concentrations exhibited pronounced in-
ter- and intra-tumoural variations. Initial intra-operative
ﬂuorescence is directly linked with the mean intra-tumou-
ral PpIX concentrations and the clinical outcome. This
could be used within an implicit dosimetry model for opti-
mising treatment parameters and for an early treatment
prognosis as well as for selection of patients suitable for
iPDT. The observation of longterm survival for all cases of
strong ﬂuorescence is encouraging and deserves further
investigation. Prospective clinical trials with higher pa-
tient numbers are highly warranted.
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Summary
Background:  Photodynamic  therapy  (PDT)  combined  with  stenting  is  an  effective  treatment
modality for  palliation  of  nonresectable  cholangiocarcinoma  (CC).  A drawback  of  standard  PDT
using Photofrin® as photosensitizer  is the long  lasting  skin  photosensitivity  of  up  to  3 months.
The aim  of  this  study  was  to  show  the  outcome  of  PDT  of  CC,  potential  side  effects  and  to
determine  the  best drug  light  interval  (DLI)  using  mTHPC  (Foscan®)  at a  low  dose.
Methods:  13  patients  with  nonresectable  CC were  treated  with  stenting  and  PDT  (3 mg  Foscan®
per  treatment,  0.032—0.063  mg/kg  body  weight,  652  nm,  50  J/cm).  Fluorescence  measurements
were performed  with  a  single  bare  ﬁber  for  5/13  patients  prior  to  PDT  at  the  tumor  site  to  deter-
mine the  ﬂuorescence  contrast.  For  another  7/13  patients,  long-term  ﬂuorescence-kinetics
were measured  on  the  oral  mucosa  to  determine  the time  of  maximal  relative  ﬂuorescence
intensity.
Results: The  results  so  far indicate  a  median  survival  time  of  13  months.  Side  effects  such  as
perforations or  skin  phototoxicity  could  not  be  observed.  Foscan® ﬂuorescence  within  the  tumor
site was  clearly  detectable  but  a  signiﬁcant  ﬂuorescence  contrast  of  tumor  to  adjacent  healthy
tissue could  not  be found.  The  ﬂuorescence  kinetics  measured  in the  oral  mucosa  showed  a
maximum  at  3.85  days  (median)  after  drug  administration.
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Conclusion:  Combined  stenting  and  PDT  performed  with  a  low  Foscan® dose  results  in  equal  and
potentially  longer  survival  times  compared  to  standard  Photofrin® PDT,  while  lowering  the  risk
of side  effects  strongly.  Thus  it  may  improve  the  quality  of  life.
©  2013  Elsevier  B.V. All  rights  reserved.
Introduction
The  incidence  rate  of cholangiocarcinoma  (CC)  varies
strongly  throughout  the world  [1].  The  yearly  incidence  in
Western  Europe  amounts  to  about  3—5 per  100,000  with
an  increasing  trend  [2].  The  only  curative  therapy  is  the
complete  resection  or  liver  transplantation.  However  at
diagnosis  the  tumor  is  mostly  at  such an  advanced  state  that
resection  is  no  longer  possible  [3].  For palliative  treatment
commonly  stents  are inserted.  Nevertheless  the  prognosis
for  patients  with  nonresectable  CC  is  still  fairly  poor. While
the  mean  survival  time  for  patients  treated  with  stents
alone  is  about  6 months,  stenting  combined  with  photody-
namic  therapy  (PDT),  commonly  performed  with  Photofrin®
or  Photosan®,  has  been  shown  to  be  a  promising  alternative
palliative  treatment  form  [4,5].  In addition  to  a  reduction
of  cholestasis  and an  improvement  in  quality  of life,  a  meta-
analysis  showed  an increase  of  the  mean  survival  time  by  265
days  [6].  Thus  this  combined  treatment  modality  is  compa-
rable  to  incomplete  R1  and R2  resections  [4].
For  PDT,  a photosensitizer  is  applied  to  the  patient  and
activated  by  light of  an  appropriate  wavelength.  Depending
on  the  type  of photosensitizer  employed,  activation  results
in  the  build-up  of  different  radicals  and  reactive  oxygen
species,  such  as  singlet  oxygen,  which  in  turn  cause  cellular
damage  [7].  PDT  is  primarily  a  local  treatment  restricted  to
the  illuminated  tissue.  However,  the immune  system  could
be  stimulated  by  local  PDT, which  might result  in the  addi-
tional  treatment  of  distant  metastases,  as  demonstrated
in  animal  models  [8,9].  Another  advantage  of  PDT is  that
very  little  photosensitizer  accumulates  in  the nuclei  [10],
whereby  the  DNA remains  comparably  unaffected  [11].  Fur-
thermore,  a dose  accumulation  as  in radiotherapy  does  not
occur.  In  view  of  the given  aspects  and the minor side
effects,  mainly  skin  photosensitization,  PDT  can  thus  be per-
formed  repetitively.  The  type of  photosensitizer, its dosage
and  the  drug  light interval  (DLI)  are  selected  in dependence
of  the  treatment  site  and stage  of the  tumor.  Until now,  PDT
for  CC  is  commonly  performed  with  the ﬁrst  generation  pho-
tosensitizer  Photofrin®.  A  great  drawback  using  Photofrin®
is  the  patients’  long  lasting  skin  photosensitivity  requiring
shielding  from  intense  sunlight  for  up  to  3 months.  Addition-
ally  the  therapeutic  penetration  depth  for  Photofrin®-based
PDT  is  limited  to  approximately  4—6  mm  [5].  Another  pho-
tosensitizer  is  Protoporphyrin  IX  (PPIX),  the  direct  precursor
of  heme,  which  accumulates  after  exogenous  administration
of  5-aminolevulinic  acid  (5-ALA).  PPIX shows  a low systemic
toxicity  and  a  short  period  of  skin  photosensitivity  of  24—48  h
[12].  However,  PDT  with  5-ALA  for  the cholangiocarcinoma
was  stated  to  be  unsuitable  because  of  its  therapeutic  pen-
etration  depth  of  less  than  2  mm  [13]  and  the resulting
insufﬁcient  reduction  of bile duct stenoses  [14]. Thus  the
need  for  a  better  photosensitizer  is  evident.
A  promising  photosensitizer  for  PDT of  cholangio-
carcinoma  is  meso-tetrahydroxyphenylchlorin  (mTHPC,
Foscan®).  Compared  to  Photofrin® it has  a  high  quantum
yield  for  PDT  reactions,  an activation  at  longer  wavelengths
which  results  in  a  deeper  therapeutic  penetration  and a
reduced  period  of photosensitivity.  Foscan® was  approved
in  2001  in the  EU  for  the  palliative  treatment  of  head
and  neck  cancer  with  a maximal  dose  of 0.15  mg/kg  body
weight,  a ﬂuence  of 20  J/cm2 and  a DLI  of 96  h [15].
With  a dose  of  0.15  mg/kg  b.w.  and  excitation  light  at
652  nm  the  therapeutic  penetration  depth  is  expected  to
be about  9  mm  [16]. Though  in  general  desirable,  such  a
deep  therapeutic  penetration  can  also  result  in compli-
cations  such as  perforations,  when treating  hollow  organs
[17,18].  By  reducing  the  Foscan® dose, these  risks might  be
lowered.  In  addition,  the  skin  phototoxicity  lasting  about
2—4  weeks  after  the  full  dose  may  be  reduced  further  by
using  lower  Foscan® doses  [19]. In a study  performed  by Betz
et  al.  [20], patients  with  basal  cell carcinomas  (BCCs)  were
treated  with  reduced  Foscan® doses  of  0.03—0.15  mg/kg
b.w.  with  correspondingly  adjusted  ﬂuences  and DLIs.  For
the  complete  dose range  they  could  report  on  complete
remissions  of  BCCS  in 96.7%  of the cases,  whereas  side
effects  such as  pain  and  phototoxic  reactions  were  reported
to  be  more  common  in patients  treated  with  a  high  drug
dose  (0.06—0.15  mg/kg).  In  line  with  these  results,  PDT of
cholangiocarcinoma  was  performed  in the present  study
with  Foscan® at 3 mg per  treatment,  which  resulted  in a
mean  dose  of  0.044  ±  0.007  mg/kg  b.w. (mean  ±  SD)  and  a
range  of 0.032—0.063  mg/kg  b.w. The  necessary  ﬂuence  was
assumed  to  be 50  J/cm2 instead  of  the  standard  20  J/cm2 to
compensate  for the  reduction  of  the drug  dose.
A  patient  oriented  DLI-determination  for low  dose
Foscan® treatment  of  cholangiocarcinoma  is  missing  so
far.  Different  ways to  determine  the DLI for PDT  are  dis-
cussed  in the  literature,  as  the  optimal  DLI may  vary for
different  PDT approaches.  For  example  the optimal  time
point  for light  irradiation  may  be either the  peak  drug
concentration  in plasma  [21],  the time  with  the maxi-
mum  ﬂuorescence  contrast  of  cancerous  to  normal  tissue
[22]  or  the peak  drug  concentration  in the target  tissue
[22,23].
It  was  the  aim  of  the present  study  to investigate  the  DLI
and  the PDT-response  applying  a  reduced  dose  of  Foscan®
in individual  treatment  attempts  for PDT  of cholangiocar-
cinoma.  The  reduced  drug  dose  was  chosen  with  the main
intent  to  reduce  the risk  of perforations  and  the  side  effects,
especially  the skin  photosensitivity.
Materials and methods
Foscan® was  used in individual  treatment  attempts  as  off-
label  use  for  PDT of  cholangiocarcinoma.  The  patients  were
informed  about  the  off-label  use  of  Foscan®,  and  written
informed  consent  was  obtained  from  each  patient.  The  study
was  approved  by  the Munich  Institutional  Review  Board  of
the  Ludwig-Maximilians-University.
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Table  1  Details  of  patients,  bismuth  types,  PDT  parameters  and  ﬂuorescence  measurements.
Patient Treatment Sex  Age  Bismuth  type  DLI [h]  Foscan® dose
[mg/kg  b.w.]
Fluorescence
contrast
measurements
Fluorescence
kinetics
measurements
1  1 Female  55  IV 20  0.045  Yes  No
2 2 Male  67  IIIb 20  0.046  Yes  No
3 3 Male  76  IV 20  0.043  Yes  No
4 4 Male  72  IIIb 20  0.042  Yes  No
5 5 Male  86  IV 20  0.054  Yes  (Yes)
6-1 6 Female  71  IV 20  0.041  No  No
7 7 Male  68  IIIb 20  0.041  No  No
8 8 Male 66 IIIb 20  0.046  No  No
9 9 Female 81 II 20 0.063  No  (Yes)
10 10  Male  83  I 70  0.035  No  (Yes)
11 11  Male  62  IIIb 70  0.038  No  Yes
6-2 12  Female  71  IV 72  0.041  No  Yes
12 13  Male  60  I 67  0.032  No  Yes
13 14  Male  83  IIIa 67  0.043  No  Yes
(Yes): ﬂuorescence measurements without standardization.
In  total,  13 non-selected  consecutive  patients,  3 females
and  10  males,  with  advanced  nonresectable  cholangiocar-
cinoma  and  clinically  signiﬁcant  bile  duct  stenoses  were
investigated  over  a  period  of  25  months  from  May 2010
onwards.  The  mean  age  was  72  years,  ranging  from  55  to
86  years.  For  1  of  the  13  patients,  PDT  was  performed  a  sec-
ond  time  one  year  after  the ﬁrst  treatment,  resulting  in a
total  of  14  PDT  treatments  investigated  in  the present  study
(Table  1).  According  to  the Bismuth-Corlette  classiﬁcation
[24], 4  patients  were  categorized  as  Bismuth  type  IV,  6  as
type  III,  1  as  type  II, and  2  as  type  I.  The  diagnosis  was  con-
ﬁrmed  by  histopathology  in 9 patients.  For the remaining
4  patients,  histology  showed  inﬂammation  but  no  malig-
nant  cells.  For  these  patients  diagnosis  was  based on  typical
endoscopic  and  radiologic  ﬁndings  (hilar strictures  and  hilar
tumor  mass  in  CT/MRI).  No  patient  had  distant  metastases  at
the  time  of  PDT, but  1 patient  had local  peritoneal  carcinosis
without  ascites.  All patients  underwent  endoscopic  retro-
grade  cholangiopancreatography  (ERCP)  combined  with  PDT
for  endoscopic  drainage  of  bile  duct  stenoses.  In  patients
typed  Bismuth  II—IV, 2  or  3  biliary  drainages  (double-pigtail
catheters)  were  placed  and  changed  by  ERCP  every  2—3
months  during  follow  up.  ERCP  procedures  were  accompa-
nied  by  antibiotic  therapy.
For  5  of  the  13  patients  ﬂuorescence  was  measured  dur-
ing  ERCP  and  prior  to  PDT-irradiation  in the tumor  stenosis
and  the  adjacent  healthy  bile  duct.  In these  patients,  the
ﬂuorescence  probe  was  brought  into  gentle  contact  with
the  mucosa  under  direct  visualization  by  through-the-scope
cholangioscopy  (SpyGlass®,  Boston  Scientiﬁc,  Natick,  MA)
and  documented  by  video.  For  another  7 of the 13  patients,
ﬂuorescence-kinetics  measurements  were  performed  in the
oral  mucosa  after  Foscan®-administration.
Protocol  for PDT
While  in  head  and neck  PDT-treatment  protocols  patients
receive  Foscan® at a dose  of 0.15  mg/kg  b.w.,  all 13  patients
included  in the present  study  were  given  Foscan® (Biolitec
pharma  Ltd.,  United  Drug  House,  Magna  Drive,  Dublin  24,
Ireland)  at a  ﬁxed  dose  of 3 mg for  practical  reasons.  With
patients  body  weights  ranging  from  47.9  to  92.4  kg  this
resulted  in  a dose  range  of  0.032—0.063  mg/kg  b.w. and  a
mean  dose of  0.044  ±  0.007  mg/kg  b.w. (mean  ±  SD).  The
lipophilic  Foscan® was  slowly  applied  via a  central  venous
catheter  during approximately  5 min with  simultaneous  infu-
sion  of  a common  lipid  solution  to  avoid  photosensitization
of a peripheral  vein. The  ﬁrst  9 treatments  were  performed
after  a DLI of  20  h.  According  to  the  results  of  the  ﬂuores-
cence  kinetics  performed  during  treatment  5 and  9, DLIs
of  67—72  h  were  chosen  for  the  following  5  treatments,  as
shown  in Table  1.
PDT was  performed  with  laser  light  at 652 nm  (Ceralas,
Biolitec,  Jena,  Germany).  The  stenoses  were  irradiated  by
means  of  a  cylindrical  light diffuser  of  4  cm  length  (Light
Guide  Optics  GmbH,  Rheinbach,  Germany).  By  reposition-
ing  the  diffuser,  the complete  lengths  of  the stenoses
were  irradiated,  applying  a  ﬂuence  of  50  J/cm  at  a ﬂuence
rate  of 200  mW/cm.  The  choice  of this  ﬂuence  is  based
on the  assumption  that  the  bile  duct has  a  diameter  of
approximately  3 mm and the  consideration  that  a cylinder
with  a  diameter  of  3  mm  has  a surface  of  1 cm2 per  1 cm
length.  Multiple  backscatter  in  the  cylindrical  organ  was  not
accounted  for,  potentially  increasing  the expectable  treat-
ment  depth.  For stenoses  of the hilar  bifurcation,  parts  of
the  common  bile  ducts  were  irradiated  twice,  so  that  the
light  dose at the overlapping  sites  (2—3  cm)  added  up  to
100  J/cm.
During  the  ﬁrst  six  days  after  Foscan® administration,
daylight  exposure  was  not  allowed  and  the  patients’  room
was  illuminated  with  yellow  light below  200  Lux.  Patients
had  to cover  their  skin  and  wear  dark  sunglasses  when  leav-
ing  their  rooms.  Typically  on  the sixth  day,  the lights  were
changed  to  common  white  lights  and  after  seven  to  eight
days  the patients  were  discharged  from  hospital.  Patients
were  advised to shield  from  direct  sunlight  and  strong
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artiﬁcial  light  sources  for  approximately  another
week,  according  to  the standard  patient  information
leaﬂet.
For  analysis  of  the  PDT outcome  side  effects  and survival
time  were  evaluated  as  efﬁcacy  parameters  of  this study.
Survival  time  was  analyzed  by  Kaplan—Meier  analysis.
Fluorescence  measurements
In  the  initial  5  of  the 13  patients  ﬂuorescence  measure-
ments  were  performed  within  the tumor  region  and  adjacent
healthy  bile duct tissue  prior  to  PDT to  determine  the con-
trast  of  the relative  ﬂuorescence  intensity  between  these
tissues.
Fluorescence  kinetics  in the  oral  mucosa  were  mea-
sured  for  3  patients  without  standardization,  as  indicated
in  Table  1.  In  an additional  4 patients,  standardized  mea-
surements  were  performed.  Measurements  were  performed
directly  before  drug administration  and  thereafter  once  or
twice  a  day  until  the patients  were  discharged  from  hos-
pital,  which  was  commonly  on  day 7 or  8. For  1  patient,
ﬂuorescence  kinetics  could  be  measured  for 48  days,  since
he  underwent  additional  treatment  in  the same  hospital.  For
3  of  the  4  patients  also  the ﬂuorescence  kinetics  of the  skin
were  measured.
For  comparison  purposes  ﬂuorescence  kinetics  in  one  sin-
gle  patient  of  the head and  neck  department  suffering  from
a  pharyngeal  squamous  cell carcinoma  (SCC) and  receiving
standard  Foscan® PDT (0.15  mg/kg  b.w.)  could  be  measured.
The  relative  ﬂuorescence  intensity  could  be  measured  for
days  1—13  on healthy  tissue  of  the  oral  mucosa.
The  ﬂuorescence  measurements  were  performed  by
means  of  a  ﬁber  based  probe.  Excitation  light  of  a violet  laser
diode  module  (Flexpoint® Lasermodule,  Laser  Components,
Olching,  Germany)  emitting  at 405  nm  was  coupled  into  a
50%  arm  of  a ﬁber  based  50/50  beam  splitter  (multimode
coupler,  ATI  optique,  Courcouronnes,  France)  with  400 m
core  diameter. For the contrast  measurements  a single  bare
ﬁber  with  a  core  diameter  of  400 m  was  connected  to  the
100%  arm  as sensor,  which  was  pushed  through  the  working
channel  of  a  cholangioscope  and  pressed  gently  onto  the  tis-
sue.  The  power  of  the excitation  light emitted  at the ﬁber
tip  was  measured  to  be  350  W.  The  ﬂuorescence  emitted
from  the  tissue  was  collected  by  the same  single  ﬁber  and
was  transmitted  through  the second  50%  arm  of the  beam
splitter,  in  which  a  long  pass  ﬁlter  (435  nm,  colored  glass
ﬁlter,  Schott  AG, Mainz,  Germany)  was  integrated  to  block
the  excitation  light.  Fluorescence  spectra  were  detected  by
a  miniature  spectrometer  in  the spectral  range  from  339
to  1029  nm  (Oceans  Optics  USB2000+,  Mikropack,  Ostﬁldern,
Germany)  which  was  connected  to  the beam  splitter.  At  each
site  1—13  single  spectra  were  recorded  after  slight  reposi-
tioning.
For  the  ﬂuorescence  measurements  in  the oral  cavity  the
same  set-up  was  used,  only  using  a different  ﬁber  with  a
core  diameter  of  375 m  as  sensor. The  ﬁber  was  hand-held
and  its  tip  pressed  gently  onto  the oral  mucosa  of the  cheek.
On  each  cheek,  9 measurements  were  performed,  trying  to
measure  3  times  in  the same  region  but  repositioning  the
ﬁber  slightly  each time  to  prevent  bleaching  effects.  For
the  same  reason  the integration  time  was  minimized.
Spectra  evaluation
In  order  to account  for  possible  day to  day variations
of  the laser  light  intensity,  a  solid  ﬂuorescence  standard
was measured  before  each session.  Data  was  processed
using  MATLAB® (The  MathWorks,  Inc.,  Natick,  MA).  When
processing  the  data,  ﬁrst,  all detected  spectra  were normal-
ized  to  the  integration  time,  the dark  background  intensity
determined  and  subsequently  subtracted  from  each  raw
spectrum.  The  autoﬂuorescence  background  was  considered
by  ﬁtting  and subtracting  an exponential  decay.  From  these
spectra  the maxima  of  the ﬂuorescence  peaks  at 652  nm
were  extracted.
For  treatments  11—14,  ﬂuorescence  kinetics  after
Foscan® administration  were  measured  in  the oral  mucosae.
For  each measurement  session  the  mean  of  the  maxima
of  the 18  measurements  and  the  standard  deviation  were
calculated.  For  calibration  purposes  the  mean  values  and
standard  deviations  were  divided  by  the peak  intensity  of the
ﬂuorescence  standard.  To determine  the normalized  max-
ima  intensities  and  the time  points  at which  they  occur,
all  kinetics  were curve  ﬁtted  by  Eq.  (1),  which  was  derived
by  considering  the  Foscan® administration  as  a  bolus  injec-
tion.  If so, Foscan® pharmacokinetics  can be  satisfactorily
described  by  a  simple  two  compartment  model  [25],  the  ﬁrst
compartment  being  the  vasculature  with  rate  constants  for
losses  by  excretion  and  transport  into  the second  compart-
ment,  the cells  of  the tissue  to  be measured.  The  second
compartment  has losses  for  efﬂux  of  Foscan® also  accounted
for  by  a  rate  constant.  Considering  both  compartments
results  in a  function  of  the following  form  (Eq.  (1))  where  a,
b  and  c  can  be determined  by the initial  drug  concentration
and  the rate  constants:
f(t)  =  a ·  (1 −  exp(b · t))  ·  exp(−c  ·  t).  (1)
Results
Fluorescence  contrast
For  5 of  the 13  patients,  the Foscan® ﬂuorescence  was  mea-
sured  prior  to  PDT  by  means  of  ERCP  as  to  determine  the
contrast  of  malignant  to healthy  bile  duct  tissue.  For  com-
parison,  the relative  ﬂuorescence  was  also  measured  in  the
oral  mucosa.  Fig.  1 shows  the  resulting  relative  intensities
normalized  for each  patient  to  the mean  of the ﬂuorescence
intensity  measured  at the site  of  the tumor.  Unfortunately,
the  measurements  for  patient  2  in the healthy  bile  duct
could  not  be  evaluated  due  to  technical  reasons.  For  the
other  measurements  the ﬂuorescence  varies  strongly,  even
for  the  same  tissue  sites,  so  that  a  signiﬁcant  selectivity
of  Foscan® in malignant  versus  healthy  tissue  could  not  be
demonstrated  for the bile  duct.  Still,  it could  be demon-
strated  that  Foscan® does  accumulate  in the  malignant
tissue.  Nonetheless,  ﬂuorescence  measurements  in  the  bile
duct  were  not  proceeded.  They  prolonged  the ERCP  and
therefore  treatment  resulted  to  be  more  stressful  for  the
patients,  while  gaining  additional  knowledge  could  not  be
expected.  However  the  relative  ﬂuorescence  measured  for
patients  3,  4  and  5 in oral  mucosa  lies  within  one standard
deviation  of  the ﬂuorescence  measured  in the tumor,
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Figure  1  Normalized  mean  ﬂuorescence  and  standard  devia-
tion  measured  by  means  of  endoscopic  cholangioscopy  prior  to
PDT treatment  for  malignant  tissue,  healthy  tissue  of  the  bile
duct  and  oral  mucosa  (for  patient  2  ﬂuorescence  was  measured
at the  tongue  instead  of  the  cheek).  Foscan® peak  intensities
are normalized  to  the  mean  tumor  ﬂuorescence  intensity  of
each patient.  The  numbers  at  the  bottom  of  each  bar  represent
the number  of  measurements  included.
justifying  measurements  in the oral  mucosa  as  indicator  for
the  ﬂuorescence  in  the tumor.
Fluorescence  kinetics
In  Fig.  2  the  results  of  the ﬂuorescence  kinetics  measure-
ments  are  shown.  Fig.  2a  shows  the  long  term  kinetics  for
patient  11  and  the  least  squares  curve ﬁt based  on  Eq.
(1).  Fig.  2b  shows  the  standardized  ﬂuorescence  kinetics
measurements  of  all  4 patients  until  day  9.  To  evalu-
ate  the  variation  of  these kinetics  a boxplot  diagram  of
the  extracted  maximum  ﬂuorescence  intensity  values  after
curve  ﬁtting  is  shown  in Fig.  3a. For  3  of these 4 patients,
ﬂuorescence  kinetics  were  also  measured  at the skin.  The
kinetics  curves  are  not  shown  but  the ﬂuorescence  inten-
sities  of  the  maxima  are plotted  in the boxplot  diagram
in  Fig.  3a.  Also  the maxima  of  the  ﬂuorescence  intensities
measured  in  the  oral mucosa  and  skin  measured  in the head
and  neck  patient  administered  0.15  mg/kg  b.w. Foscan® are
included  for  comparison  (marked  by  +).  From Fig.  3a  it  could
be  derived  that  according  to  the  curve  ﬁts  after  normaliza-
tion  to  the  standard  the median  of  the normalized  maxima
is  0.029  and  the  mean  value  0.031.  The  relative  intensities
measured  at  the  skin  are lower, with  a median  of  0.0032
and  a  mean  of  0.004.  The  ratio  of  the mean  values  of  oral
mucosa  and  skin  is  7.75.  For  the head and neck  patient  the
normalized  maximum  is  0.069  for  oral mucosa  and  0.012  for
skin.  The  ratio  of  oral  mucosa  to  skin  is  5.75  and is  thus  in
the  same  range  as  the ratio  of  the  low dose  patients.  For the
ratio  of  normal  and  low dose a  factor  of  2.2  results  for  oral
mucosa  and  a  factor  of  3  for  skin.
In  Fig.  3b  a boxplot  diagram  of  the  times  to  maximal
intensity  is  shown.  For oral  mucosa  the time  to maximum
intensity  equals  3.85  days  (median)  and  the mean  3.95  days.
For  comparison,  the  time  to  maximum  in oral  mucosa  for
Figure  2  Fluorescence  kinetics  measured  on  oral  mucosa
after  administration  of  3 mg  (0.032—0.063  mg/kg  b.w.)  Foscan®:
(a) for  patient  11  measured  over  a  period  of  48  days,  (b)  for  4
patients measured  up  to  9 days,  for  clarity  standard  deviations
are plotted  only in  one  direction.
the head and  neck  patient  occurring  at 3.08  days  is  indi-
cated  as  well.  For  the  ﬂuorescence  kinetics  of the skin  for
all  patients,  the  variation  of the data  points  were very  large
and  the  slope  of  the kinetics  between  day  2 and  5  was  close
to  zero  so  that  times  to  maximum  intensity  could  not  be
derived  reliably  from  the  curve ﬁt.
PDT outcome
The  overall  survival  times  were  analyzed  by  Kaplan—Meier
analysis  with  95%  conﬁdence  intervals,  as  shown  in  Fig.  4.
PDT  was  performed  3  months  (median)  after  diagnosis.  As
can  be seen  in the Kaplan—Meier  survival  curve,  5 of  the 13
patients  died  6, 7, 8, 9 and  13  months  after  diagnosis.  All
deceased  patients  were  categorized  with  Bismuth  III or  IV.
The  patient  who  died  6  months  after  diagnosis  developed
metastases  in lung  and  bones,  which was  diagnosed  1  month
after  PDT  and  might  have been present  at PDT  already.
The  patient,  who  died  7 months  after  diagnosis  had  liver
abscesses,  which  were  detected  during  PDT-ERCP.  A  subse-
quent  CT showed  local  peritoneal  carcinosis,  in addition.
Please  cite  this  article  in press  as: Kniebühler  G, et al.  Photodynamic  therapy  for  cholangiocarcinoma  using  low dose
mTHPC  (Foscan®).  Photodiagnosis  and Photodynamic  Therapy  (2013),  http://dx.doi.org/10.1016/j.pdpdt.2012.12.005
ARTICLE IN PRESS+ModelPDPDT-452; No. of Pages 9
6  G.  Kniebühler  et  al.
Figure  3  Fluorescence  kinetics  measured  on oral  mucosa
and  skin  after  administration  of  3 mg  (0.032—0.063  mg/kg  b.w.)
Foscan®:  (a)  box  plot  diagram  of  the  intensity  maxima  derived
from the  two  compartment  curve  ﬁt  for  all  4 patients  of  oral
mucosa  measurements  and  for  3 of  the  4  patients  for  skin
measurements,  (b)  box  plot  diagram  of  the  time  to  maximal
intensity  for  oral  mucosa  kinetics  as  derived  from  the  curve  ﬁt,  •
indicates  mean  values,  + indicates  the  intensity  maxima  as  well
as the  time  to  the  maxima  after  administration  of  0.15  mg/kg
Foscan®.
Even  with  the 4  early  deceases  — the censored  8 patients
are  still  in  the  follow  up  —  the median  survival  time  results
to  13  months.  When  only regarding  patients  with  Bismuth
types  III  and  IV  the median  results  to  11  months.
For  10  of the  13  patients,  temporary  ailment  in  the upper
abdomen  during  the  ﬁrst 48  h (median)  followed  the treat-
ment.  This  could  have been  evoked  either  by  PDT or  by  the
accompanying  ERCP.  Nausea  was  reported  by  7  patients.  All
ailments  were  easily  treated  by  analgetics  and  antiemetics.
Apart  from  this,  the ﬁrst  patient  developed  an acute  self-
limiting  edematous  pancreatitis,  and  endoscopy  revealed  a
Figure  4  Kaplan—Meier  diagram  of  13  treated  patients  for
overall  survival  after  diagnosis.  Patients  deceased  6,  7, 8, 9 and
13 months  after  diagnosis.  The  other  8 patients  are still  in the
follow  up.
local  ulcer  at the  papilla.  This  was  likely  caused  by  long  local
irradiation  with  the endoscopic  xenon  light during  a long
lasting  cholangioscopy.  As  a consequence,  the endoscopic
light  was  turned  off in the subsequent  procedures  if a stable
endoscopic  position  had  been  achieved.  No  other  local  com-
plications  and, especially,  no  perforation  occurred.  None  of
the  patients  experienced  skin  irritations  during  their  hospi-
tal  stay,  nor  did any  of  the  patients  report  on  skin  irritations
later  on.
Discussion
PDT  using  Photofrin® as  photosensitizer  is  effective  for
treatment  of nonresectable  hilar  cholangiocarcinoma.  Dis-
advantages  of Photofrin® include  a  long  period  of general
phototoxicity  and  a limited  penetration  depth  at  the  tumor
site.  In contrast,  the  light  penetration  depth  is  greater  with
Foscan® and  the duration  of  general  phototoxicity  is  much
shorter.  In  the present  study,  Foscan® was  introduced  at a
low  dose  as  photosensitizer  for  PDT of  cholangiocarcinoma.
The  main  ﬁndings  were  as  follows:  (1)  a  signiﬁcant  Foscan®
ﬂuorescence  was  detectable  at the  tumor  site already  20  h
after  administration.  (2)  Foscan® did not  accumulate  at  the
tumor  site compared  to  the adjacent  healthy  tissue.  (3)
The  optimal  drug-light  interval  was  three  to four  days.  (4)
PDT  using  Foscan® was  effective  in  terms  of  survival.  (5)  No
severe  side  effects  could  be  observed.
Fluorescence  contrast
In  the present  study, a Foscan® dose  of 3 mg  per  treat-
ment  resulting  in 0.032—0.063  mg/kg  b.w. and DLIs  of  20
and  67—72  h  were  used  for PDT  treatment  in contrast  to the
approved  0.15  mg/kg  b.w. at a DLI  of  96  h  for  head  and  neck
cancer.  The  choice  of  a  short  DLI  and a  low Foscan® dose
was  based  on  the  publications  of  Triescheijn  et  al. [21], who
found  a  DLI  of  24  h  to  be best  for treating  basal  cell carcino-
mas  (BCCs)  with  0.1  mg/kg  bodyweight  Foscan®,  and  of  Betz
et  al.,  describing  treatment  outcomes  of  patients  with  BCCs
with  administered  doses  ranging  from  0.03  to  0.15  mg/kg
b.w.  and  DLIs  ranging  from  1 to  96  h  [20]. For patients
treated  with  0.05  mg/kg  b.w.,  a ﬂuence  of  50  J/cm2 and  a
DLI  of 48  h,  complete  remission  was  reported  in 100%  of  the
cases  and  reducing  the photosensitizer  dose  to  0.04  mg/kg
b.w.  with  shortening  the DLI to  24  h  yielded  an only  slightly
lower  remission  rate.  The  good  remission  rates  with  short
DLIs  might be explained  by  the  study  of  Braichotte  et al.
[26],  who  found  the highest  contrast  between  squamous  cell
carcinomas  and  normal  tissue  as  early  as  2—4  h  after  drug
administration  (high  dose regime),  which  may  represent  a
rapid  distribution  within  the vascular  system  followed  by  a
rapid  decrease.
For  the determination  of  the optimal  DLI,  however,  both
the  contrast  versus  healthy  tissue  and  the absolute  con-
centration  in  the  tumor  tissue  have  to  be  considered.  As
the highest  accumulation  occurs  later  than  the highest  con-
trast  [26—28],  the  decision  on the DLI is  a  compromise.  In
this  study  with  a reduced  drug dose, attention  was  paid  to
maintain  a sufﬁcient  drug  accumulation  in  the tumor  tissue.
Therefore,  for  the  sake  of  efﬁcacy,  the  focus  was  on  the
drug  concentration  rather  than  on  the  maximum  contrast.
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As  the  drug  accumulation  is  usually  a broad  peak,  a DLI  of
20  h  seemed  to  be  a reasonable  compromise  for  the present
study.  Measurements  of  Foscan® ﬂuorescence  intensities  in
the  bile  duct  and  on  oral  mucosa  were  intended  to  quan-
tify  the  contrast  in  CC  patients.  By using  a single  bare ﬁber
with  a  small  core  diameter  for  the ﬂuorescence  measure-
ments,  the  optical  tissue  properties  do  not inﬂuence  the
ﬂuorescence  measurements  strongly  [29,30].  Therefore  it  is
a  reasonable  approach  to  compare  the measured  ﬂuores-
cence  in  different  tissues  to each  other.  When  interpreting
the  ﬂuorescence  measurements  within  the  tumor  stenoses
prior  to  PDT,  however,  it has  to be  kept  in mind  that  posi-
tioning  the  ﬁber  within  a bile  duct stenosis  is  difﬁcult  even
with  guidance  by  direct  cholangioscopy.  A vertical  position-
ing  of  the  ﬁber  onto  the  tissue  cannot  always  be  assured.
It  proved  unexpectedly  time  consuming  to  capture reliable
spectra.  After  having  investigated  5  patients,  it was  decided
to  discontinue  these  measurements  to  avoid  undue  stress  to
the  patients.
Moreover,  bile  duct stenoses  due  to  CC  usually  consist
of  a  mixture  of  tumor  tissue,  inﬂammation,  and necrosis,
and  even  forceps  biopsies  from  tumor  stenoses  have  a sen-
sitivity  of  only  43—88%  [3].  Therefore,  the  measurements
might  not  vary  only  because  of  concentration  differences
but  also  due  to  difﬁculties  in positioning  the ﬁber  repro-
ducibly  in  smooth  contact  with  the tissue  and because  of
the  nature  of the tissue  itself.  Nevertheless,  although  the
measured  relative  ﬂuorescence  intensities  in  malignant  tis-
sue  are  not  signiﬁcantly  different  from  the  Foscan® levels
within  the  surrounding  healthy  tissue,  the  ﬂuorescence  mea-
surements  indicate  that  20  h after  administration,  there  is
a  signiﬁcant  Foscan® accumulation  in malignant  tissue.  Any
further  conclusion  about  absolute  Foscan® concentration  or
tumor  selectivity  cannot  be  made  due  to  the  high  variations
in  signal  intensity  for  both  tissue  types,  the low number  of
measurements  and the impossibility  to  measure  pharmaco-
kinetics  in  the  bile  duct.  However, the small  and inconsistent
differences  in the ﬂuorescence  contrast  between  the tumor
and  the  normal  tissue  of  the bile  duct led to  the  conclusion
that  the  short  DLI  of 20  h  needs  to  be  questioned.  Instead
it  was  intended  to  ﬁnd  the  time  point of  maximum  accumu-
lation  of  Foscan® by  measurements  of  ﬂuorescence  kinetics
at  a  better  accessible  site.
Fluorescence  kinetics
Apart  from  the  practicability,  measuring  ﬂuorescence  in the
oral  cavity  to  gain  information  of  the  photosensitizer  present
in  the  bile  duct  was  triggered  by  Glanzmann  et  al. [28]. They
measured  the  relative  ﬂuorescence  with  ﬂuorescence  spec-
troscopy  in  21  patients  prior  to  PDT in the  bronchia,  the
esophagus  and  the oral  cavity,  ﬁnding  a  linear  correlation
between  the  relative  ﬂuorescence  of  the esophagus  and  the
oral  cavity.  This  suggests  that  information  of  the  relative
ﬂuorescence  in  the bile  duct  may  also  be  gained  by  mea-
suring  the  relative  ﬂuorescence  in the  oral  mucosa,  though
of  course  the  kinetics  might differ. The  ﬂuorescence  kinet-
ics  measured  in the  present  study  show  a maximum  at day
3.85  (92  h,  median)  after  Foscan® administration.  This  is  in
good  agreement  with  the ﬂuorescence  kinetics  measured  in
the  oral  mucosa  for  high  dose  (0.3  mg/kg  b.w.)  published  by
Braichotte  et al.  [26],  who  also  showed  that  the maximum
relative  ﬂuorescence  intensity  in tumor  tissue  occurs  earlier,
varying  with  the  tumor  type,  by  approximately  20—30  h. As
the  kinetics  measured  in the  present  study  for  low  dose  are
similar  to  those  of  high  dose,  a  DLI  of  68—72  h  was  chosen
for  the  last  four patients.  In addition,  this DLI choice  allows
to  delay  the treatment  by  a day  without  endangering  the
treatment  efﬁciency.
PDT outcome
Although  a  low Foscan® dose  was  used in this study,  the
median  survival  time  after  diagnosis  is  13  months.  This  is  in
the  range  found  in previous  retrospective  studies  using  the
photosensitzer  Photofrin® or  Photosan-3® for  PDT of  non-
resectable  cholangiocarcinoma  [4,31—34]. Keeping  in mind
that  8  out  of 13  patients  are still  in the  follow  up,  PDT  with
a  low dose  of  Foscan® seems  to  be a promising  treatment
modality.
Pereira  et  al. were  ﬁrst  to  treat  CCs  with  a dose  of
0.15  mg/kg  b.w. Foscan®.  They  included  4  patients  with  hilar
CCs  in  their  study.  PDT  combined  with  stenting  resulted
in  survival  times  of  1—12  months  [18]. However, they  also
reported  on  2  severe  complications,  assumed  to  be  related
to  PDT  with  high  Foscan® doses,  one with  post-mortem  evi-
dence  of  a perforated  gallbladder,  and  2  patients  had  hand
erythema  during  the ﬁrst  2 weeks.  They  concluded  that  com-
bined  stenting  and PDT prolongs  life  compared  to  stenting
alone  and can  increase  quality  of  life,  but  a signiﬁcant  risk
of  complications  has  to  be  accepted.  Wolkersdörfer  et  al.
reported  on the  treatment  of 11  patients  with  hilar  bile
duct  cancer  using  also  a Foscan® dose  of  0.15  mg/kg  b.w.
[17].  They  focussed  on  the therapeutic  depth  and  found it
doubled  compared  to  PDT performed  with  Photofrin® while
a  similar  rate  of infectious  complications  and  skin  photo-
toxicity  occurred.  They  also  had  to  report  on  one  case  of
bile  duct  wall  perforation.  In  the  same  study  four patients
showed  phototoxic  skin  reactions,  one  severe  (grade III)  and
three  grade  I or  II.
To our  knowledge  this study  is  the ﬁrst  reporting  on  PDT of
CCs  performed  with  a low  dose  of  0.03  mg/kg  b.w. Foscan®.
A  great  advantage  using  Foscan® at a  low  dose  is  the,  based
on the  outcome  of  the present  study,  expected  decrease
in  side  effects  during  treatment  as  well  as  during the  follow
up.  In the present  study,  neither  serious  complications  due  to
PDT  nor  any  other  side  effects  apart  from  temporary  ailment
in  the upper  abdomen  or  nausea  could  be  registered.
A  major  reason  for  the  low  phototoxicity  of  a  low  dose
of  Foscan® may  be the reduced  amount  of  Foscan® present
in  healthy  tissue,  such  as  the  skin,  as  shown  in  the ham-
ster  cheek  pouch  model [35]. The  comparison  of  the relative
ﬂuorescence  measured  in the  head  and  neck  patient  admin-
istered  0.15  mg/kg  b.w. Foscan® conﬁrms  this,  though  it is
only  one  data  point  measured.  With  this  restriction,  the
peak  intensities  found  in oral  mucosa  after  low  dose Fos-
can  were  lower  by  a factor  of  2.2,  those  in skin  were  lower
by  a factor  of 3. As  a consequence,  the risk  of  developing
skin  edema,  erythema  or  sun  burns  when exposed  to  sunlight
or  intense  room  light is  reduced  compared  to  the standard
drug  dose. Assuming  a  similar  pharmacokinetics  for  high  and
low  drug  doses,  as  suggested  by  the present  results,  skin
Please  cite  this  article  in press  as: Kniebühler  G, et al.  Photodynamic  therapy  for  cholangiocarcinoma  using  low dose
mTHPC  (Foscan®).  Photodiagnosis  and Photodynamic  Therapy  (2013),  http://dx.doi.org/10.1016/j.pdpdt.2012.12.005
ARTICLE IN PRESS+ModelPDPDT-452; No. of Pages 9
8  G.  Kniebühler  et  al.
photosensitivity  can  also  be  expected  to  be  considerably
shortened.  This  is  in good  agreement  with  the lack  of  symp-
toms  caused  by  skin  photosensitization  observed  in  the
present  study.
As all  5  deceased  patients  had high  Bismuth  types  (III  and
IV),  one  might  conclude  a  limited  beneﬁt  for these  more
advanced  cases.  However,  the  median  survival  regarding
only  high  Bismuth  type patients  is  still  11  months,  with  5
of  these  patients  still  alive.  It may  therefore  be  too  early
to  ﬁnally  conclude  that  low dose  Foscan® PDT  is  inferior
to  PDT  using  Photofrin® or  Photosan-3® for  this  group  of
patients.  In  addition,  individual  factors  such  as  local  compli-
cations,  comorbidity,  and  the presence  of distant  metastases
as  shown  in  our  cases  would  be  of  greater  importance  for
survival  than  the Bismuth  stage  irrespective  of  the kind  of
photosensitizer  used.  In  view  of  the low  side  effect  proﬁle
observed  so far, the quality  of  the survival  time  appears  to
be  in  favour  of  low  dose  Foscan® and  may  further  argue
for  using  low  dose  Foscan®.  Especially,  since  for  palliative
treatments  of  cholangiocarcinoma  in  patients  with  a  limited
prognosis,  the  according  beneﬁt  with  regard  to  quality  of  life
is  very  important.  Moreover,  it may  allow  for  repeated  PDT
treatments  [31]  and  may  also  qualify  PDT  as  a neoadjuvant
therapy  before  surgery  of  resectable  cholangiocarcinoma
[36].
Conclusion
The  results  of  this  study  suggest  that  nonresectable  CC  can
be  treated  with  a low dose  of Foscan® at 3  mg  resulting
in  0.032—0.063  mg/kg  b.w., a  light  dose  of  50—100  J/cm
at  652  nm  applied  by  radial  diffusers  and  DLIs  of  67—72  h.
The  outcome  seems  to  be  comparable  to standard  PDT  using
Photofrin®.  No local  side  effects  occurred,  and  compared
with  both  Photofrin® and  Foscan® in the high  dose  regime,
skin  photosensitivity  is  expected  to  be  considerably  reduced
in  severity  and  duration.  In  addition,  when using  a low  dose
of  Foscan®, the  treatment  is  more  cost-effective.  The  use-
fulness  of  low dose  Foscan®-PDT  for  cholangiocarcinoma
should  be  investigated  in further  controlled  studies.
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